2

3

4

5

6

7

8 9

10

11

12

13

1415

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

Discovery of a novel antibiotic, Transitmycin, from *Streptomyces* sp unveils highly efficient activities against tuberculosis and human immunodeficiency virus Vanaja Kumar*^{1,4}, Balagurunathan Ramasamy², Mukesh Doble ^{\$3,5}, Radhakrishnan Manikkam⁴, Luke Elizabeth Hanna¹, Gandarvakottai Senthilkumar Arumugam^{3,7}, Kannan Damodharan³, Suresh Ganesan³, Azger Dusthakeer¹, Precilla Lucia¹, Shainaba A Saadhali¹, Shanthi John², Poongothai Eswaran², Selvakumar Nagamiah¹, Jaleel UCA⁶, Rakhila M⁶, Ayisha Safeeda⁶ and Sathish S⁶ ¹National Institute for Research in Tuberculosis, Chennai – 600031, Tamilnadu, India ²Department of Microbiology, Periyar University, Salem – 636011, Tamilnadu, India ³Department of Biotechnology, Indian Institute of Technology, Madras – 600036, Tamilnadu, India ⁴Centre for Drug Discovery and Development, Sathyabama Institute of Science and Technology (Deemed to be University), Chennai – 600119, Tamilnadu. India ⁵ Saveetha Dental College and Hospitals, 62, Poonamallee High Rd, Chennai, 600077, India ⁶ Open Source Pharma Foundation-National Institute of Advanced Studies Drug Discovery Lab, NIAS, IISc Campus, Bangalore, Karnataka, India ⁷SSS International Drug Discovery & Development Research Private Limited, Innovation & Entrepreneurship, Sudha & Shankar innovation hub, IIT Madras, Chennai-600036, India Email: *vanaja kumar51@yahoo.co.in; \$ mukeshdoble.sdc@saveetha.com **Abstract** HIV is identified as a factor that aggravates tuberculosis disease pathogenesis and its progression to latent TB. While, TB is declared as one of the major causes for AIDSassociated mortality. So there is a dire need for new drugs to combat such ailments that have a synergistic interaction. This has led us to study a novel antibiotic purified from a marine Streptomyces sp isolated from the coral reef ecosystem of South Indian coast. Streptomyces sp. R2 (MTCC 5597; DSM 26035)., isolated from the marine water was grown on agar plates and the crude yellowish orange pigment secreted was extracted using various solvents. The antibiotic, named as Transitmycin, was purified and tested against M. tuberculosis, drug resistant strains, and M. tuberculosis biofilm. The compound was also tested against HIV-1 viruses belonging to six subtypes. Several characterisation tools were used to elucidate the structure of this novel antibiotic. Transitmycin was derivitaised to elucidate the absolute configurations of the amino acids present in it. Tr, unlike actinomycin D, has L-valine in both the rings instead of D-valine (found in the latter). Also, one of the proline in Tr is in D-NOTE guiration mucholts new search compression and in the control of the control

- 36 compound and is not reported so far. It exhibits dual activities against the standard H37Rv,
- 37 49 drug sensitive clinical isolates, and MtB biofilm as well as standard and 20 clinical
- isolates of HIV. This is the first paper that reports the isolation of a new antibiotic from
- marine actinobacteria exhibiting unusual anti-TB and HIV activities which could be exploited
- 40 further as a lead molecule in the quest for the design of drug with dual activities.
- 42 Highlights

51

52

- A novel antibiotic was purified from a marine Streptomyces sp isolated from the coral
- 44 reef of S. India
- Presence of L-valine, not observed in actinomycin D, and one of the proline in D
- 46 configuration suggest that it is a novel structure not reported before
- It exhibits activity against standard MtB strain as well as clinical isolates and drug
- 48 resistance ones
- It exhibits anti-HIV activity against several clinical isolates
- Key words: Antibiotic, *Streptomyces* sp., Actinomycin, Transitmycin, Tuberculosis, HIV,

Introduction

- Despite, the history of infectious diseases is time immemorial, an urgent need for protection
- 54 against infectious diseases has one of the major health concerns. Antibiotics have
- revolutionized the diagnostic factor in various aspects and the drug discovery is considered as
- 56 a hallmark in human history. However, the concomitant development of resistance against
- 57 diseases is the most serious consequence [1]. In 2020, an overall rate of 1.5 million people
- 58 pretentious from TB. In fact, TB is one of the leading sources of death, wherein occupied the
- 59 13th position and moreover the second foremost infective destroyer after COVID-19 (above
- 60 HIV/AIDS). Since it is an airborne infectious disease caused by *M tuberculosis*, continues to
- be a major cause of mortality and morbidity worldwide [2].
- An upsurge of multi drug resistance (MDR) and extensively drug resistance (XDR) is
- an additional perturbing factor in tuberculosis chemotherapy. Comprehensively, the existing
- treatment for TB based on half yearly quadruple therapy containing rifampicin, isoniazid,
- ethambutol and pyrazinamide results the cure rate of 90-95% [3] for drug-sensitive TB at
- global level. Nevertheless, this regimen is inadequate to treat MDR and XDR-TB infections,
- 67 sometimes the second line antibiotics are employed to treat MDR-TB infections for
- 68 prolonged time whereas XDR infections are almost untreatable. Different TB drugs with
- 69 unique mode of action are desperately necessary to fight against drug resistant tuberculosis.

For example, bedaquiline and delamanid are approved for drug resistant TB, however due to the reported toxicity issues, they may employ only on last resort [4]. In addition, the second line drugs used to treat MDR-TB with several disadvantages such as less efficacious, more toxic, and more expensive than the first-line drugs [5]. At presently progressing anti TB drugs should partake essential properties like succeed a short therapy period (sterilizing effect), a simpler regimen, capable of act on MDR/XDR-TB, concurrent treatment of TB/HIV and advanced safety level than the existing drugs [6]. Alike the human immunodeficiency virus (HIV) leads to destruction of the immune system resulting a condition termed as Acquired Immuno Deficiency Syndrome (AIDS). After its finding AIDS becomes a great risk to humans, reflected to be pandemic and it is the greatest public health crisis in globally. As of 2021, millions of people living with HIV were rescuing antiretroviral therapy [7]. Several researches have been developed the drugs against HIV disease, such as the growth of many antiretroviral drugs (ARVs), including the atazanavir, ibalizumab, darunavir, abacavir, zidovudine, lamivudine, efavirenz, tenofovir disoproxil fumarate, tenofovir alafenamide, emtricitabine, bictegravir, cabotegravir, rilpivirine etc. nevertheless, the competency of HIV intensive to mutate rapidly leads to the upsurge of drug resistance to existing anti-retrovirals [8]. Since the finding of penicillin, many of the microbial natural products tends to the new paradigm for novel drug discovery development [9,10].

Over the past 60 years, [11] the microbial bioprospecting has gained a remarkable quantity of medicinal components, including actinobacteria, the major bacterial phylum group of Gram-positive bacteria with guanine and cytosine (G+C) rich content in their genomic sequence, which are the important prokaryotes in economic and ecological manner. Significantly the existence of actinobacterial multiplicity in several rare ecosystems liable for prolific producers of many biologically active natural compounds with different potential activities [12-15]. Some of the pharmaceutical companies have dramatically declined in the result of novel wide range antibiotics in the past few decades [16]. Obviously, this critical state has caused in the surplus of such antibiotics with distinct mode of activity targeting the arcade, wherein this precluded the assessment of usual terrestrial sources in particular for actinobacteria and led scientists to pursuit unique habitats on the marine family for novel bioactive molecules [12,17,18]. Indeed, actinobacteria are ubiquitous in the marine environment, which are occupying a substantial ecological characteristic in the recycling and production of novel natural products with huge pharmaceutical applications [19].

Generally, the 16S rRNA gene sequencing has concomitantly employed to identify, classify and quantitation of microbes in multifaceted biological molecules. It is obvious from

the 16S rRNA sequencing that marine microbial species as bacteria and archae have an extreme different taxonomy. Even the 16S rRNA sequences of more than ten thousand actinomycetes had been isolated hitherto from marine outsources. The discovery of novel secondary metabolites from marine actinobacteria has just surpassed that of their terrestrial counterparts [15]. According to the review of Blunt et al., [20] shown that there are 179 new natural products isolated during 2016, in which the actinobacterial genus *Streptomyces* remains to be the dominant source. An extensive study on typical marine actinobacterial genera like *Salinispora* and *Verrucosispora* produces salinosporamide and abyssomycin respectively, which suggest that actinobacteria improves significant feature towards marine drug discovery research [21]. Further, marine based antibiotics are more ingenious in combat infections due to the terrestrial bacteria do not have chance to develop resistance against them [22]. During the microbial bioprospecting process, the actinobacterial extracts isolated from various less-explored ecosystems were screened for anti-TB and anti-HIV activity. The isolation, characterization and potential bioactivities against TB and HIV of an antibiotic obtained from a marine *Streptomyces* sp. R2 is being reported herewith.

Results and Discussion

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

Description of the actinobacterial strain

- 122 Transitmycin is a depsipeptide (bicyclic) molecule produced by actinobacterial strain R2,
- which was isolated from the sediment samples from Rameswaram coral reef ecosystem (Lat.
- 9.2876° N; Long. 79.3129° E), Tamil Nadu, South India using Starch Casein Agar (SCA)
- supplemented with nalidixic acid (20µg/ml) and nystatin (100µg/ml). Viability of strain was
- maintained in International Streptomyces Project-2 (ISP2) agar slants, 30% glycerol broth
- followed by lyophilisation. It was also deposited in Microbial Type Culture Collection
- 128 (MTCC), India and in DSMZ German Collection of Microorganisms and Cell Cultures,
- 129 Germany. (R2 = MTCC5597; DSM26035).

130 Characterization and taxonomy

- The characterization of a strain is the key element in classification of prokaryotes including
- actinobacteria [23]. Actinobacterial classification was initially based mainly on
- morphological and physiological characteristics [24-25]. The onset of chemotaxonomic
- standards has provided reproducible and reliable data to identify the genera at genus level
- 135 [26]. This microbial strain R2 under microscopic observation showed the presence of dense
- aerial and substrate mycelia with long, un-fragmented spore chains with hairy structures
- (Supplementary Fig. 1a-b). The physiological and biochemical characteristics of the strain R2

are given in Supplementary S-Table 1. Strain R2 showed good growth in various ISP media and utilized a wide range of carbon and nitrogen sources. In addition, good growth was also observed at different physiological conditions. Notably, the extracellular yellow pigment production was greatly influenced by nitrogen substrates, pH, temperature and NaCl. Strain R2 produced lipase and amylase. High sensitivity was observed for most of the antibiotics tested (Supplementary S-Table 1). The cell wall analysis revealed that the strain R2 is rich in LL-2,6-Diaminopimelic acid (L-DAP) and glycine. No diagnostic sugars were found in the cell wall constituents. In our present study, the results of phenotypic characterization and cell wall analysis indicated that the actinobacterial strain R2 belongs to the genus *Streptomyces*, however it is not adequate for differentiation at species level.

Furthermore, the PCR (Polymerase Chain Reaction) amplification of 16S rRNA gene of strain R2 formed around 1400 base pair sequence and the BLAST (Basic Local Alignment Search Tool) analysis have shown 99% similarity to the 16S rRNA gene sequence of *Streptomyces variabilis* (EU570414) and other closely related species submitted in GenBank. Phylogenetic relationship of the strain R2 and related taxa are given in Supplementary S-Fig. 1c.

The 16S rRNA gene sequence of strain R2 has the accession number HQ012501at GenBank, but this gene provides limited resolution for species level identification, since it discloses more extensive genotypic differences. At this stage, the average nucleotide identity (ANI) [27] of all preserved genes between any two genomes shows likely to reform taxonomy, because it also correlates with the best DNA: DNA Hybridization (DDH) values. The most often used standards for species delineation i.e. the 70% DDH [28] which is closely equivalent to 95% ANI (Average Nucleotide Identity) values. Moreover, no organisms have been defined hitherto has shown <98.7% identity in their 16s rRNA gene and shown <95% ANI or 70% DDH. These results supported the substitution of cumbersome DDH and related procedures with simple sequence-based standards. Significantly the metabolic property of transitmycin production had not been reported before from any other meticulously associated Streptomyces species. Based on the aforesaid facts, the actinobacterial strain R2 is identified to be a novel strain of Streptomyces variabilis, but still it showed 99% similarity with its associated proximity neighbors. It is very important to mention here that there is no literature evidence on any commercially available antibiotic, in particular anti-TB and/or anti-HIV compounds from Streptomyces variabilis.

Transitmycin production

The growth of Streptomyces sp. R2 is simultaneously observed with grey colour aerial mycelia and soluble yellow orange pigment in good yield. The crude compound is extracted well in several solvents namely, methanol, chloroform and dichloromethane, followed by diethyl ether and ethyl acetate (Supplementary Table 2). The extracts in the former solvents were intensely coloured when compared to the extracts from the latter solvents. Salts and debris were present in the extracts while using former solvents, so ultimately ethyl acetate was chosen for extracting the bioactive pigment. The activity of the crude extract was also tested on different strains of M. tuberculosis. More than 95% reduction in Relative Light Units (RLU) was observed through Luciferase Reporter Phage Assay against all three M. tuberculosis strains. When 1.0 L of YEME agar was used for production it yielded 800 mg crude antibiotic extract in ethyl acetate. Major antibiotics reported from actinobacteria are extracellular in nature [29-30]. Industrial production of many antibiotics from Streptomyces is achieved through submerged fermentation process [31]. In contrast, some actinobacterial strains are found to produce antibiotics only on solid media and very little reason is reporeted as to why activity is restricted to solid culture and not observed in submerged cultures. Shomura et al reported [32] that about 1300 out of 6500 actinomycetes showed antimicrobial activity against one or more of the test organisms when tested by agar plug method. In the secondary screening, about 25 (1.9%) of the 1300 strains were found to be non-producers in submerged cultures. So, we conlcude that the reports of


According to Mayurama *et al.* [33] fumaridamycin was detected with much difficulty in submerged cultures, because the mycelium of the producing strain inactivate the antibiotic more readily in liquid than in agar culture. Similarly, Shomura*et al* [32] demonstrated that the antibiotic produced by *Streptomyces halstedii* has shown activity against Gram negative bacteria only in agar dishes, which correlates well with its mycelial morphology. The aerial mycelium was filamentous during antibiotic production in solid cultures, but fragmented in non-producing liquid cultures. Similar to report from Shomura *et al.* [32] the bioactive pigment production by the *Streptomyces* strain R2 was observed only in agar culture, where the vegetative mycelium was filamentous. While decreasing the concentration of YEME broth from 2X to 1/10X the mycelia filamentation was found to increase. However, none of the five concentrations of YEME broth produced the pigment (unpublished data). This outcome evidenced that the filamentous mycelial structure does not influence pigment production by the strain R2 in broth while the bioactive pigment production was observed in all the concentrations of YEME agar when filamentous mycelia was formed. In accordance to

antibiotics isolated from only agar cultures of actinomycetes are very rare.

Ohnishi *et al.* [34] who reported that 2-aminophenoxazin-3-one containing grixazone A and B, afford yellow pigments during phosphate depletion by *Streptomyces griseus*. By adopting these strategies, it was concluded that optimizing the medium components may trigger the pigmented bioactive compound production by our isolated *Streptomyces* sp. R2 in liquid cultures.

Transitmycin purification, characterization and structure elucidation

The *Streptomyces* sp. R2 was found to produce 800 mg of crude pigment per litre of yeast extract malt extract medium in agar surface fermentation. The yellow-orange pigment was separated from the crude ethyl acetate extract by TLC and column chromatography and its purity was confirmed by HPLC analysis (Supplementary Fig S13-S17). Primarily the three well separated spots viz. R1, R2 and R3 with R_f values of 0.8, 0.6, 0.3, respectively were observed on analytical TLC using EtOAc:MeOH (9.5:0.5) solvent system. In bioassay directed isolation, fraction R1 (named as Transitmycin) showed more than 95% inhibition against M. tuberculosis strain H37Rv in LRP assay. It was isolated as an orange colour amorphous powder with $[\alpha]_D^{25}$: -106° (c = 0.2, MeOH). The R1, R2, R3 in crude extract and as purified compounds R1, R2, R3 showed similar retention time in RP-HPLC chromatograph (Fig, 1a-d). A single peak of transitmycin at a RT of 5.8 minutes confirmed its purity (Fig. 1c).



227 Fig. 1. Representative HPLC chromatogram of crude and isolated samples R1, R2 and R3. a 228 RP HPLC of Chromatogram of crude extract of *Streptomyces* sp. R2. **b** RP HPLC analysis of 229 mixture of R1, R2, R3. C RP HPLC of Chromatogram of pure Transitmycin R1. d 230 Transitmycin R1 obtained after column chromatographic purification. e UV-Vis spectra of 231 Transitmycin R1, R2 and R3. f IR Spectrum of Transitmycin R1. 232 The chemical structures of these molecules (R1, R2 and R3) were elucidated by UV-Visible, IR, CD, ¹H, ¹³C, DEPT 135 NMR, 2D NMR (¹H-¹H COSY, ¹H-¹H DQF-COSY, ¹H-¹H 233 ¹H-¹³C HSQC, ¹H-¹³C HMBC, NOSEY, ROESY) and MALDI-TOF-MS, HR-234 TOCSY, 235 ESIMS, HR-EIMS, HR-LCMS, and 3200 QTRAP-LC/MS/MS analyses and also compared 236 with the previously reported NMR and Mass data of actinomycins (Supplementary 237 Information) [35-57]. Advances in spectroscopic techniques have mainly utilized for 238 compound identification and immensely accelerated the unambiguous representation of compound characterization and structural elucidations. The UV-Vis spectrum of 239 240 Transitmycin showed a strong absorption band around (λ_{max} 214, 240, 425, 442 nm (in MeOH) (Fig. 1e). The colour and absorption peak in UV-Vis analysis revealed the presence 241 242 of phenoxazinone chromophore. Singh et al. [58] and Maskey et al. [59] detected the presence of phenoxazinone chromophore in bioactive metabolites from Streptomyces sp. and 243 244 Actinomadura sp. The absolute configuration of the amino acids were supposed to be 245 identical to that of actinomycin D, as indicated by the negative optical rotation values and the 246 strong cotton effect at about 210 nm in the CD spectra. The CD values of Transitmycin (R1) 247 are: [MeOH, [nm], (mdeg)] $\lambda_{\text{max}}(\Delta \epsilon)$ 195 (+24.0), 210 (-21.5), 241 (+1.7). 248 In the IR spectrum, a strong absorption broad band appears at around 3435 cm⁻¹, an 249 intense strong peak at 1746 cm⁻¹ and a band around 1099 cm⁻¹ are assignable to be amino (or 250 hydroxyl), lactone ring and alicyclic 6-membered ether type (C-O) groups, respectively. IR data of transitmycin (R1) (KBr cm⁻¹), 3435 cm⁻¹ for NH, 2958, 2924 cm⁻¹ (m, -CH str. asym. 251 252 CH₃ and CH₂), 2872 cm⁻¹, 2853 cm⁻¹ (m, -CH str, sym, CH₃ and CH₂),1746 cm⁻¹ (s, C=O str, lactone ring), 1642 cm⁻¹(s, -C=O str, 2° amide), 1524, 1503 (m, -NH bend, 2° amide), 1466 253 (m, CH bend (scissoring), CH₂), 1379 cm⁻¹ (s, -CH bend, isopropyl group), 1268 (s, C-O str, 254 255 ester), 1194 (C-O-C of lactone) 1099, 1059, 1017 (s, C-O or C-N), 720, 712, 694, 689 (s, -256 CH bend, oop, aromatic ring), 909 (w, CH₃ rocking) [48] (Fig. 1f).

The ¹H and ¹³C NMR spectra exhibited the typical features of two (alpha and beta ring) pentapeptido lactone ring attached with phenoxazinone chromophore, i.e., each ring

257

contained four amide carbonyl resonances and one ester carbonyl in one ring (δ_C 168.8, 173.4, 173.1, 166.2, 167.4 (α -ring) and 168.9, 173.9, 172.7, 166.4, 167.4 (β -ring), together with phenoxazinone chromophore (101.8 (C-1), 147.3(C-2), 179.0 (C-3), 113.4 (C-4), 144.9 (C-4a), 140.3 (C-5a), 127.6 (C-6), 130.2 (C-7), 126.0 (C-8), 132.1(C-9), 128.4 (C-9a), 14.9 (C-11), 7.6 (C-12), 166.0 (C-13), 165.8 C-14). One of the amino acid proline in the β -ring contained a keto group (208.0 in the 13 C NMR). From 1 H NMR spectrum, NH of amino acids (δ_H 8.23, β -L-Valine), (δ_H 7.74, α -L-Valine), (δ_H 7.69, β -L-Threonine, (δ_H 7.2, α -L-Threonine), (δ_H 6.55, 2H of β -proline) (δ_H 5.93 2H of α -proline) and four N-methyl groups (δ_H 2.91, 2.88, 2.89, 2.87) (Fig. 2 a-d). In addition, the 1 H NMR spectra of Transitmycin indicated the presence of eight methyl groups arising from four isopropyls.

NOTABLE CHARACTERISTIC ¹H NMR SPECTRA OF DIFFERENT PROLINE UNITS OF TRANSITMYCIN (R1), R2, R3




Fig. 2 Notable characteristic ¹H NMR spectra of different proline units of Transitmycin as **a** R1 (4-oxoproline). **b** R2 (proline) and **c** R3 (4-OH proline). **d** Comparative studies for ¹H NMR (500 MHz, CDCl₃) chemical shift value of NH containing amino acid residue and chromophore motifs of Transitmycin (R1), R2 and R3.

The UV/Vis absorption spectra with maximal absorbance at 240 nm and 442 nm support the presence of an amino phenoxazinone chromophore in its structure. From ¹H - ¹H COSY and TOCSY experiments, five amino acid systems namely Pro, Thr, Val, N-Methyl Val, and Sar were identified. The assignments of the protonated carbons were obtained from the HSQC spectrum, in combination with inspection of the HMBC spectrum. By comparison of

the UV spectrum (λ_{max} 442 nm, in MeOH) of Transitmycin with that of actinomycin series (λ_{max} 440 nm, in MeOH) (Fig. 1e) it was concluded that the former contained an aminophenoxazinone chromophore residue. In ¹H NMR, two *ortho* coupled protons at 7-H, 8-H; δ_{H} 7.56 and 7.34 corresponding to 1,2,3,4-tetrasubstituted aromatic ring, and two 3H singlet at δ_{H} 2.52 (11-CH₃) and 1.95 (12-CH₃) of methyl groups in peri-position of the aromatic system were identified. This is the characteristics of phenoxazinone chromophore found in various actinomycins.




Fig. 3. **a** Key ¹H-¹H COSY correlation of Transitmycin (R1). **b** Key ¹H-¹H TOCSY correlation of Transitmycin (R1). **c** Key ¹H-¹³C HMBC connectivity for Transitmycin (R1). **c** ¹H-¹H ROESY correlation of Transitmycin (R1). **d** Chemical structure of isolated compounds Transitmycin (R1). **e** R2. **f** R3.

The result was further confirmed by HMBC correlations between the 7-H (δ_H 7.59) and 8-H (δ_H 7.34) of the tetra substituted double bond and the carbonyl resonances at δ_C 166.0. The carbonyl carbons of Pro, Thr, Sar, Val, and N-methyl Val, were clearly assigned to (δ_C 179.0, 174.0, 173.1, 169.02, 198.8, 167.5, 166.5, 166.56, 166.3, 166.1 and 165.9) on the basis of the observed correlations between carbonyl groups protons of the same amino acid residue in the HMBC spectrum. All the residues were connected on the basis of DQF-COSY, TOCSY, HMBC, ROESY and NOESY correlations (Fig. 3a-c), thus establishing the amino acid sequences and overall constitution. (Supplementary Fig. S14-65, S-Table 5). The detailed analysis of ^1H - ^1H COSY, ^1H - ^1H DQF-COSY, ^1H - ^1S C HMBC, and ^1H - ^1S C HSQC, ^1H - ^1H

TOCSY, ¹H-¹H NOESY, ¹H-¹H ROESY NMR spectra [35-51] (Supplementary Information 299 Fig. S14-65, S-Table S5) and MALDI-TOF-MS (Fig. 4a-m and Fig. 5) and HR-ESIMS, HR-300 301 LCMS, ESI-MS, QTRAP LC-MS/MS [52-57] (Fig. 5, S-Table S6), (Supplementary 302 Information Fig. S14-115, S-Table S7a-b) spectral fragmentation pattern revealed ten amino 303 acids in Transitmycin (Fig. 3d), which is identical to those present in actinomycin X2 [35-57] 304 (2 X MeVal, 2 X Thr, 2 X Sar, 2 X Val, proline and ketoproline). OPro was identified by the 305 ketone moiety (δ_C 208.6 ppm) and the altered chemical shifts and coupling patterns of the 306 neighbouring methylene groups (Table 1). **Table 1**. ¹H NMR (500 MHz, CDCl₃)/¹³C NMR (125 MHz, CDCl₃) and 2D NMR (500 MHz, 307 CDCl₃) correlation spectral data of Transitmycin (R1) ¹H-¹H COSY, ¹H-¹H TOCSY ¹H-¹³C 308 HMBC, ¹H-¹H ROESY 309

α- ring	Position	δc	δ_{H}	J (Hz)	COSY	TOCSY	HMBC	ROSEY
Thr	1	168.8	-	-	-	-	-	-
	2	54.6	4.60	d , 10.0	3, 4, -NH	3, 4	1, 3, 13	3, 4, 2-Val, Val- NH
	3	74.7	5.13	m	2, 4,- NH	2, 4,	4	2, 4, Val-NH
	4	17.0	1.10	d, 6.5	2, 3	2, 3, -NH	2, 3	2, 3, Val-NH
	NH	-	7.29	d, 7.0	2, 3, 4	2, 3, 4	1, 3, 13	2, 4
L-Val	1	173.4	-	-	-	-	-	-
	2	58.7	3.58	dd, 10.5,6.5	3, 4, 5, - NH	3, 4, 5, -NH	1, 5, 1-Thr	3, 4, 5, 2-Pro
	3	31.7	2.08	m	2, 4, 5	2, 4, 5	2,5	4, 5, 4-Thr
	4	19.0	0.89	d, 7.0	2, 3	2, 3, -NH	2,3,5	2, 3, 5
	5	18.9	1.13	d, 6.5	2, 3	2, 3, -NH	2,3,4	2, 3, 2-Val, Val- NH
	NH	-	7.74	d, 5.5	2, 3, 4, 5	2, 3, 4, 5	2, 3, 1-Thr	2, 3, 4, 5, 2- Thr, 3-Thr
Pro	1	173.1	-	-	-	-	-	-
	2	56.4	5.93	d, 9.5	3a,3b,4a,4b	3a,3b 4a, 4b	3, 4, 5, 1- Val	3a, 3b, 2a-Sar,2b- Sar, Sar-NMe
	3	31.6	2.73 1.84	dd, 17.5,7.0 dd, 19.5, 6.5	3b, 4a, 4b 3a, 4a,	3b, 4a, 4b 3a, 4a,	1, 2, 4 1, 4, 5	3b, 2a-Sar, 2b-Sar 3a, 4a, 4b
	4	23.3	2.26 2.01	d, 16.5 d, 8.0	3a, 3b, 4b 3b, 4a	3a, 3b, 4b 3b, 4a	3, 5 3, 5	4b, 5a, 5b 4a, 5a
	5a 5b	47.8	3.86 3.67	d, 18.5 d, 18.5	3a, 4a, 4b 3a, 4a, 4b	3a, 4a, 4b 3a, 4a, 4b	4, 1-Val	5b
Sar	1	166.2	-	-	-	-	-	-
	2	51.2	2a, 4.70 2b, 3.64	d, 17.5 d, 17.5	2b 2a	2b, NMe 2a, NMe	1, NMe,1- pro 1, NMe,1- Pro	2b, NMe, 2-Pro 4-MeVal, 5- MeVal, NMe
	N-Me	34.9	2.87	S		2a, 2b	2, 1-Pro	2b, 3-MeVal
Me-Val	1	167.4	-	-	-	-	-	-
	2	71.3	2.70	d, 9.0	3, 4, 5	3, 4, 5	1, 3,4,NMe	4, 5
	3	26.9	2.62	d, 7.0	2, 4, 5	2, 4, 5	1, 3, 4, 5, NMe	4, 5
	4	21.6	0.96	d, 6.0	2, 3	2, 3, 5	2, 3, 5	3
	5	19.2	0.72	d, 6.5	2, 3	2, 3, 4	2, 3, 4	3
	N-Me	39.2	2.89	s	-	2, 3	2, 1-Sar	2, 3, 5, 2a-Sar, 2b- Sar

β-ring	position	δc	δн	J (Hz)	COSY	TOCSY	НМВС	NOESY
Thr	1	168.9	-	-	-	-	-	-
	2	54.9	4.50	d, 9.0	3,4, -NH	3, 4	1, 3, 14	3, 4, 2-Val, Val-NH
	3	74.6	5.23	m	2,4,- NH	2, 4	4	2,4, Val-NH
	4	17.6	1.20	d, 6.0	2, 3	2, 3, - NH	2, 3	2,3, Val-NH
	NH	-	7.68	d, 6.0	2, 3, 4	2, 3, 4	1, 3, 14	2, 4
L-Val	1	173.9	-	-	-	-	-	-
	2	57.1	3.71	dd, 10.5, 6.5	3, 4, 5, - NH	3, 4, 5, -NH	1, 3, 5, 1- Thr,	3, 4, 5, 2-Oxo pro
	3	31.8	2.20	m	2, 4, 5	2, 4, 5	2, 5	4, 5, 4-Thr
	4	19.0	0.86	d, 7.0	2, 3	2, 3, -NH	2, 3, 5	2, 3, 5
	5	18.8	1.14	d, 7.0	2, 3	2, 3, -NH	2, 3, 4	2, 3, 2-Val, Val-NH
	NH		8.23	d, 6.0	2, 3, 4, 5	2, 3, 4, 5	2, 3, 1-Thr	2, 3, 4, 5, 2-Thr, 3- Thr
Oxo- Pro	1	172.7	-					
	2	54.2	6.55	dd, 10.0, 2.0	3, 5	3, 5	3, 1-Val	3, 5, 2a-Sar, 2b-sar- NMe
	3	41.8	2.32 2.13	d, 18.5	2, 5	2, 5	1	2, 5
	4	208.0	2.13	d, 13.0	2, 5	2, 5	1 -	2, 5
	5	53.7	3.83 3.90	d, 18.5 dd, 18.5, 12.0	2, 3 2, 3	2, 3 2, 3	1, 2 1, 2	2, 3 2, 3
Sar	1	166.4	-	-	-	=	-	-
	2	51.28	2a, 4.54 2b, 3.95	d, 19.5 d, 19.0	2b 2a	2b, NMe 2a, NMe	1, NMe, 1- Pro 1, NMe, 1- Pro	2b, NMe, 2-oxo-pro 4-MeVal , 5-MeVal, NMe
	N-Me	34.7	2.88	S	-	2a, 2b	2, 1-Pro	2b, 2MeVal
Me- Val	1	167.4	-	-	-	-	-	-
	2	71.1	2.67	d, 8.5	3, 4, 5	3, 4, 5	1, 3, 4, 5, NMe	4, 5
	3	26.8	2.60	d, 8.0	2, 4, 5	2, 4, 5	1, 3, 4, 5, NMe	4, 5
	4	21.5	0.93	d, 6.0	2, 3	2, 3, 5	2, 3, 5	3
	5	19.1	0.73	d, 6.0	2, 3	2, 3, 4	2, 3, 4	3
	N-Me	39.0	2.91	S	-	2, 3	2, 1- Sar	2, 5, 2a-Sar, 2b-Sar

Position	δ_{C}	δ_{H}	J (Hz)	COSY	TOCSY	HMBC	NOESY
1	101.8	-	-	-	-	-	-
2	147.3	-	-	-	-	-	-
3	179.0	-	-	-	-	-	-
4	113.4	-	-	-	-	-	-
4a	144.9						
5	-	-	-	-	-	-	-
5a	140.3						
6	127.6	-	-	-	-	-	-
7	130.2	7.34	d, 8.0	8, 11	8, 11	5a, 9, 11-Me	11
8	126.0	7.56	d, 7.5	7, 11	7, 11	9a, 5a, 13	11
9	132.1	-	-	-	-	-	-
9a	128.4	-					
10	-	-	-	-	-	-	-
11	14.9	2.52	S	7, 8	7, 8	5a, 6, 7	7, 8
12	7.6	2.18	S	-	-	3, 4, 4a	-
13	166.0	-	-	-	-	-	-
14	165.8	-	-	-	-	-	-




Fig. 4 a-m. Comparative analysis of MALDI-TOF-MS for molecular ion peak of Transitmycin (R1), R2, R3. **a** R1 (Simulated). **b** R2 (Simulated). **c** R3 (Simulated). **d** R1 (Measured, positive mode. **e** R2 (Measured, Positive mode). **f** R3 (Measured, Positive mode). **g** R1 (Measured, Negative mode). **h** R2 (Measured, Negative mode). **i** R3 (Measured, Negative mode), MALDI-TOF-MS spectra of crude extract of *Streptomyces* sp. R2. **j** positive mode. **k** negative mode **l** Comparative analysis for HR-ESI-MS and MALDI-TOF-MS of Transitmycin (R1), R2 and R3 on various batches. **m** Characteristic retention factor (R_f) value and corresponding HR-ESI-MS data of purified compounds (Transitmycin (R1), R2 and R3).




Fig. 5. a Mass spectral fragmentation of Transitmycin (R1) obtained by MALDI-TOF-MS, **b** MALDI-TOF-MS spectrum of Transitmycin (R1). **c** Mass spectral fragmentation of Transitmycin (R1) obtained by MALDI-TOF-MS, 211- β-Ring-Val-Oxo-Pro, 233- α -Ring-Val-Pro, 294-β-Ring-Oxo-Pro-Sar-NMeVal, 295-Chromophore, 297- β-Ring-Thr-Val-Oxo-Pro, 357-α-Ring-Val-Pro-Sar-MeVal, 371-β-Ring-Val-Oxo-Pro-Sar-MeVal, 412-β-Ring-Val-Oxo-Pro-Sar-NMeVal, 412-α-Ring-Val-Pro-Sar-NMeVal+859 (Y ion), 495-β-Ring-Thr-Val-Oxo-Pro-Sar-NMeVal, 496-α-Ring-Thr-Val-Pro-Sar-NMeVal, 464 α - Ring-Thr-Val-Oxo-Pro-Sar-NMeVal, 746-Y-113 (MeVal), 747- α-Ring-Val-Pro-Sar-NMeVal+Y-MeVal+545.6, 495= β-Ring-Thr-Val-Oxo-Pro-Sar-NMeVal, 495-371=124-23=101 MeVal

339 (β-Ring-Thr-Val-Oxo-Pro-Sar), 371(β-Ring-Thr-Val-Oxo-Pro-Sar), 294 (β-Ring-Thr-Val-340 Oxo-Pro). 341 The MALDI-TOF-MS spectrum of crude extract of Streptomyces sp. R2 (Fig. 4j-k) and 342 343 measured, calculated mass of purified compounds Transitmycin (R1), R2, R3 were given in 344 (Fig. 4a-i, Supplementary Figure S70-115). The molecular formula was established as 345 C₆₂H₈₄N₁₂NaO₁₇ based on Positive HRESI-MS, which showed protonated pseudo molecular 346 ion peak [M+H] ⁺ at m/z 1270.7069 (Fig. 4a-m). It also showed intense peaks, due to Na and K adducts, at m/z 1291.8307 [M+Na]⁺ and 1307.8124. [M+K]⁺ respectively (Calcd. for 347 C₆₂H₈₄N₁₂NaO₁₇: 1291.5975: Found: 1291.8307). Fig. 4a-i Similarly, the MALDI TOF MS 348 349 spectrum of transitmycin showed intense peak in positive mode at m/z 1293.61316 $[M+Na+2H]^{+3}$ and at m/z 1309.93062 $[M+K]^{+}$ and in negative mode at m/z 1269.33344 350 351 [M-H]- (Fig. 4a-m, Fig. 4-5, Supplementary Information Fig. S115a-b). The compound R2 352 was isolated as orange red powder and its molecular formula was established as 353 C₆₂H₈₆N₁₂O₁₆ [M+Na]⁺ by positive HRESIMS. The MALDI TOF molecular ion of R2 354 showed peak at m/z 1278.95175 [M+Na+H]⁺ and negative ion mode at m/z 1255.38052 [M-355 H] For a molecular formula of C₆₂H₈₇N₁₂O₁₆Na its molecular weight is calculated as 356 1278.6261 [M+Na+H]⁺ which matches with 1278.95175, that is similar to that of 357 actinomycin D (Fig. 3e). The compound R3 was obtained as an oranges red powder and the 358 molecular formula of R3 was determined to be C₆₂H₈₇N₁₂O₁₇ from HR-ESIMS peak at m/z 359 1271.7159z $[M+H]^+$ and when calculated for the molecular formula, $C_{62}H_{87}N_{12}O_{17}$ 360 1271.6312, found to be 1271.7159 and 1277.6149 [M-OH-Na]⁺. The molecular formula of 361 R3 was established as C₆₂H₈₇N₁₂O₁₇ by positive MALDI-TOF 1294.5888 [M+H+Na]⁺ and negative mode 1268.4852 [M-H]- (Fig. 4f) which is identical to that of actinomycin 0β 362 363 (Supplementary Information Fig. S70-115, S-Table S7a-b) [52-57]. 364 The differences between compounds R1, R2, R3 were becaue of the variation in proline at 4th position. Transitmycin (R1) has keto group in the 4th position, R2 does not have keto 365 group and compound R3 has hydroxyl group in the 4th position (Fig. 3a-c). 366

367

368

HPLC Analysis of L-FDAA Derivatives of Transitmycin (R1)

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

HPLC experiment was used to determine the absolute configuration of isolated compounds. The absolute configurations of the amino acids were assumed to be identical to that of actinomycin X₂, as indicated by the negative optical rotation values and the strong cotton effect at about 210 nm in the CD spectra. The assignment of the amino acids was carried out primarily by the analysis of the ¹H-¹³C HSQC and ¹H-¹H-COSY correlations, MALDI-TOF-MS (Fig. 4 a-m, S-Table S6), QTRAP LC-MS/MS (Supplementary Information Fig. S14-114, S115a-b, S-Table S7a-b), and completed with the help of HMBC spectrum (Fig. 3a-c). Additionally, a small amount of compound Transitmycin and R3 were hydrolyzed and the free amino acid were analyzed by HPLC, HR-LCMS, HR-ESIMS after chiral derivatization with Marfey's reagent. Altered proline and sarcocine were not available as reference. Although neither the altered proline and threonine moieties nor N-methylated alanine were available as references, they can be assumed to possess L-configurations due to the fact that the exchange of a single amino acid with its enantiomer leads to significant conformational changes of the respective peptidolactone ring, resulting in reduced biological activities as well as chemical shift deviations that have not been observed. The absolute configuration of the threonine, valine, methyl valine, proline in Transitmycin (R1) was clarified by Marfey's method applied for the acid hydrolysate of Transitmycin (R1) in comparison with standard amino acid analysis [60-64]. Retention times of the standard N^{α} -(5-fluro-2,4-di-nitrophenyl)-L-alanamide (FDAA) derivatives were as follows: D-threonine, 15.682 min; L-threonine, 13.987 min; D-proline, 17.035 min; L-proline, 16.519 min; D-valine, 21.244 min; L-valine, 19.248 min; D-N-methyl valine, 22.089 min; L-Methyl valine 20.814 min. The chromatogram of the FDAA derivatives of acid hydrolysate Transitmycin (R1) showed peaks corresponding to L-Threonine (14.021 min), L-proline (16.520 min), L-valine (19.252), L-N-methyl valine (21.263 min) were obtained in the hydrolysate. The above same mentioned procedure for compound R3 was also done and similar results was obtained. (Supplementary Information Fig. S116-125, Table S-8a-b) [60-64]. Comparison, with authentic standards, revealed the presence of L-MeVal, L-Thr and D-Val as expected, however the D-Valine is in L-configuration as well as one of the proline is in D-proline instead of L-configuration. (Fig. 6a-c).




Fig. 6. a HPLC data analysis for L-FDAA derivatives to hydrolysates of Transitmycin R1 and standard amino acids. **b** Graphical representation for RP-HPLC chromatogram of L-FDAA (Marfey's) derivatives of hydrosylated Transitmycin (R1). **c** HR-LCMS data analysis for L-FDAA derivatives to hydrolysates of Transitmycin R1 and standard amino acids.

LC-MS Analysis of L-FDAA Derivatives of Transitmycin (R1)

The retention times of the D- and L-FDAA derivatives of standard amino acid, respectively, were as follows: Pro: 14.35, 14.97, min, *m/z* 366.13 [M +H]+, *m/z* 363.07 [M-H]+;Val:19.63,17.52 min, *m/z* 370.13 [M+H]+, 368.13 [M-H]-;Thr: 9.90, 13.50 min, *m/z*372.07 [M+H]+, 370.13 [M - H]-; NMeVal: 20.33, 19.23 min, *m/z* 384.20[M+H]+382.20 [M -H]-. The L-FDAA was used to derivatize the acid hydrolysates of Transitmycin (R1), R3 and eight standard amino acids (D-Val, L-Val, D-Thr, L-Thr, D-N-MeVal, L-N-MeVal, D-Pro and L-Pro). The reaction with L-FDAA was performed with the same procedure as above. [63-64].The retention times of the L-FDAA derivatives were as follows: D-Pro:15.16 min, L-Pro:14.31 min, *m/z* 366.13 [M+H]+ 363.07 [M-H]-;D-Val: 19.65 min, L-Val 17.65 min *m/z* 370.13 [M+H]+368.07[M-H]-; D-Thr: 9.90 min, L-Thr, 13.50 min, *m/z* 372.13[M+H]+370.13 [M-H]-; D-N-MeVal 20.33 min, L-N-MeVal 19.25 min, *m/z* 384.20[M+H]+,382.20 [M+H]-. The retention time of L-FLDA derivatives of acid hydrolysates Transitmycin (R1) were as follows: L-threonine (13.73 min), L-Proline (14.23 min), D-Proline or keto-proline (15.36 min), L-valine (18.02 min), N-Methyl valine (19.96 min) as illustrated in Fig. 6 a-b. The retention time of L-FLDA derivatives of acid

- 423 hydrolysates (R3) (Supplementary Information Fig. S-128-161, S-Table S9 a and b) were as
- follows: to L-threonine (12.45 min) or D-threonine (9.36 min), L-Proline (14.25 min), D-
- 425 Proline or keto-proline (15.21 min), L-valine (17.49 min), N-Methyl valine (19.93).
- 426 Comparison with authentic standards revealed the presence of L-MeVal, L-Thr, L-Proline,
- 427 L-Valine and one of the Proline as in D-configuration (Fig. 6c). Hence, we named the
- unusual newly found compound as Transitmycin (Fig. 3d, Table 1& 2), a member of the X-
- 429 type [35-64].

Table 2. Physico-chemical properties of Transitmycin

Transitmycin (R1)	Properties
TLC	Single yellow spot with R _f value 0.8 (EtOAc:MeOH (9.5:0.5))
Color and consistency	Orange color amorphous powder
Yield	200 mg, 20%
Melting point (mp)	240-242°C
$[\alpha]_D^{25}$	-106 ° (c = 0.2, MeOH)
Solubility	Soluble in chloroform, dichloromethane, ethyl acetate, methanol, ethanol, acetonitrile, DMSO and water; Insoluble in Hexane
UV	(MeOH) λ_{max} (log ϵ) 214 (3.07), 240 (2.30), 425 (1.44), 442 (1.51) nm
CD	[MeOH, [nm], (mdeg)]: $\lambda_{max}(\Delta \epsilon)$ 195 (+11.1), 210 (-21.0), 242 (+4.7)
IR (KBr), v_{max}	3435, 2958, 2924, 2853, 1745, 1642, 1524, 1465, 1379, 1194, 1099, 1059 cm ⁻¹
¹ H NMR (500MHz)	Table 2
¹³ C NMR (125MHz, CDCl ₃):	179.0, 174.0, 173.5, 173.17, 169.0, 168.8, 167.5, 167.5, 166.5, 166.3,166.1, 165.9, 144.34, 145.93, 145.04, 140.5, 132.19, 130.3, 129.2, 127.8, 126.1, 113.6, 101.8, 76.7, 74.76, 74.67, 71.4, 71.2, 58.5, 57.2, 56.4, 54.9, 54.7, 54.3, 51.3, 29.6, 29.6, 29.3, 22.6, 21.7, 21.6, 19.2, 19.2, 19.09, 19.06, 18.8, 17.14, 14.11,7.77.
HRESI-MS	m/z (pos.ions) 656.9243 [M+2H] ⁺² , 1270.7069 [M+ H] ⁺ , 1291.8449 [M + Na] ⁺ 1307.9286 [M + K] ⁺ $C_{62}H_{84}N_{12}O_{17}Na$ [M + Na] ⁺ calc. 1291.5975, found. 1291.8449
MALDI-TOF-MS	m/z (pos.ions) 1293.61316 [M + Na+2H] ⁺ , 1309.93062 [M+K] ⁺ m/z (neg.ions) 1269.33344 [M-H] ⁻ C ₆₂ H ₈₄ N ₁₂ O ₁₇ Na [M+Na+2H] ⁺ calc. 1293.61950, found. 1291.61316
EI-MS: (70 ev)	<i>m</i> / <i>z</i> (pos.ions)1348.1437, 1291.4173 [M+Na] ⁺ , 1224.7363, 1191.8994, 1023.6241, 886.0243, 743.2058, 614.8185, 347.6111, 202.5464, 138.5079
LCESI-MS	m/z (pos.ions) 1291.5995 [M + Na] ⁺ C ₆₂ H ₈₄ N ₁₂ O ₁₇ Na [M+Na] ⁺ calc. 1291.5975, found. 1291.5995
CHN	Anal. calcd for C ₆₂ H ₈₄ N ₁₂ O ₁₇ : C, 58.66; H, 6.67; N, 13.24. Found: C, 59.71; H, 7.28; N, 10.19.

Determination of anti TB and anti-HIV activity

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

Activity against planktonic cultures of M. tuberculosis

Despite the introduction of new anti TB drugs, emergence of antibiotic resistance among M. tuberculosis strains remains a major challenge in tuberculosis therapy. According to WHO Global Tuberculosis report - 2022, there is a 3.1% increase in incidence of multi drug resistant and rifampicin resistant TB cases from 2020 to 2021[65]. Thus, there is a burning need for more new antitubercular drugs to tackle drug resistant tuberculosis [66]. Since 1940s, secondary metabolites and their associated derivatives have played a key role in anti-TB drugs development. This is best exemplified by an extremely active aminoglycoside, namely streptomycin, the first clinical drug that was made available against TB [67]. In a previous study, Streptocytosines A, Bamitecin and Amitecin isolated from sea water Streptomyces in Japan showed activity against M. smegmatis at 32, 16 and 8 µg/ml concentrations, respectively [68]. In another study, actinomycin X2 and actinomycin D isolated from marine Streptomyces sp. MS449 in China showed activity against M. tuberculosis H37Rv at 1.92mg/ml and 1.77 mg/ml, respectively [69]. In the present study Transitmycin, a novel molecule isolated from a marine *Streptomyces* sp. R2 picked up from coral reef ecosystem showed activity notably against drug sensitive, multi drug resistant (MDR) and mono resistant strains of M. tuberculosis at concentrations of 5 and 10 µg/ml (Fig. 7). Based on the preliminary experiment on laboratory strain, M. tuberculosis H37Rv, minimum inhibitory concentration for transitmycin was determined on clinical isolates which included 49 drug sensitive strains and 48 drug resistant strains. The drug resistant profile of the clinical isolates are given in (supplementary S-table 12). Out of 97 clinical isolates, MIC at 5 µg/ml was seen in 89 isolates and MIC at 10 µg/ml was seen in 8 isolates for transitmycin based on LRP assay.




Fig. 7. MIC of Transitmycin in micrograms per millilitre for *Mycobacterium tuberculosis* isolates susceptible to anti-TB drugs (n=49) and drug resistant to one or more anti-TB drugs (n=48) as determined by LRP assay. Sensitive strains are represented in blue colour and resistant strains are represented in brown colour.

Activity against M. tuberculosis biofilm

Bacteria can persist for extended periods of time inside the biofilm due to their ability to resist the immune system, display increased virulence and become phenotypically more resistant to antibiotics. Moreover, antibiotic concentrations required to control bacteria within a biofilm are estimated to be 100–1,000 fold greater than that is needed to treat planktonic forms. As planktonically-grown *M. tuberculosis* are unlikely to be entirely representing the bacterial load during human infection, we set out to determine how effective transitmycin can be against *M. tuberculosis* growing as a biofilm, a bacterial phenotype known to be more resistant to antibiotic treatment [70]. In the present study, *M. tuberculosis* culture showed biofilm formation in the control wells alone which could be observed by the naked eye. The wells with cells and transitmycin failed to produce biofilm. CFU determined prior to the addition of transitmycin was 1.9 x 10⁶ to 2.3 x 10⁶/ml. After 4 days of exposure with the compound, the CFU dropped to 9 x 10⁴ to 10 x 10⁴ ml. Addition of transitmycin completely killed all the cells at the end of 5 weeks (Table 3).

Table – 3. Activity of transitmycin on biofilm formation

Culture	Zero days 10 ⁵ x CFU/ml			4 days CFU/ml	Biofilm formation after 5 weeks
M. tuberculosis alone	1.1	1.8	6.6	3.6	Present
M. tuberculosis+ Transitmycin (10 μg/ml)	19.0	23.0	0. 9	1.0	0.0

Anti-HIV activity

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

The symbiotic association of TB and HIV poses a challenge to human survival in which HIV complicates the treatment and diagnosis of TB. Besides, HIV-TB patients encounter other unique problems such as cumulative toxicity, immune reconstitution inflammatory syndrome (IRIS), drug-drug interactions, lower plasma drug levels, and the emergence of drug resistance during treatment [71]. The currently available therapy for treating patients coinfected with HIV and TB requires a very high pill load. Therefore, a class of drugs that can be used to treat TB and HIV would be a real breakthrough in TB and AIDS Research. Hence, the present study also evaluated the anti-HIV activity of transitmycin. A dosedependent reduction was observed in HIV-1 p24 levels in viral culture indicating that transitmycin possessed significant anti-HIV activity. Transitmycin demonstrated good antiviral activity against the different subtypes of HIV-1 as well as clinical isolates obtained directly from HIV-infected persons. In addition, transitmycin was also active against HIV-1 viruses resistant to nevirapine and AZT (Fig. 8a). The estimated IC₅₀ value ranged between 0.19 and $0.65 \mu g/ml$ for the viruses tested. There was a >50% inhibition at a concentration of 0.1µg/ml and 80-95% inhibition at a concentration of 1µg/ml in the clinical isolates (Fig. 10b). The compound demonstrated a remarkable inhibitory effect on primary isolates belonging to various subtypes as well as to clinical isolates obtained from HIV-infected individuals. IC₅₀ values calculated for the various strains tested indicate that transitmycin is a potent inhibitor of HIV-1 under *in vitro* experimental conditions. Importantly, transitmycin also inhibited drug resistant forms of the virus, in a dose-dependent manner. These findings suggest that transitmycin holds promise as the first potent compound that can be used to

treat TB and HIV infections when they occur singly, as well as in combination as HIV/TB co-infection. (Supplementary S-table 13).




Fig. 8 a Activity of Transitmycin against different HIV-1 clades. Various concentrations of Transitmycin were tested using 100 TCID_{50} of virus belonging to 6 different HIV-1 clades as well as two drug-resistant strains. Each concentration was tested in triplicate on all the indicated viruses and mean \pm SEM values are shown in the graph. Log₁₀ -2 in the figure equals $0.01 \,\mu\text{g/ml}$, Log₁₀ -1 equals $0.1 \,\mu\text{g/ml}$, Log₁₀ 0 equals $1 \,\mu\text{g/ml}$ and Log₁₀ 1 equals $10 \,\mu\text{g/ml}$. **b** Activity of Transitmycin on clinical isolates obtained from HIV-1 infected individuals. Three concentrations of Transitmycin and two concentrations of AZT were tested against 20 clinical isolates and mean \pm SD values are shown on the graph. This experiment was performed on two different occasions.

R1, R2 and R3 intercalates with the genomic DNA of Mycobacterium tuberculosis

Actinomycin D is the structurally similar compound for R1, R2 and R3. Actinomycin D and its derivatives are reported to intercalate with the DNA and exhibits fluorescence. So, we tested R1, R2 and R3 for its properties of DNA intercalation and fluorescence. Ethidium bromide 0.5 µg/ml is used as a positive control. The relative fluorescence unit (RFU) of R1, R2 and R3 with the DNA is compared with the RFU of R1, R2 and R3 without DNA. The average RFU of Ethidium bromide was 8561429. From the experiment, it was observed that all the three compounds, R1, R2 and R3 have DNA intercalating property and exhibits fluorescence (Fig. 9).




Fig. 9 a) R1, b) R2 and c) R3 binds with the DNA and emit fluorescence in a dose dependent manner. The concentrations of R1, R2 and R3 tested were 0.5 μ g/ml, 1 μ g/ml, 2 μ g/ml and 5 μ g/ml. As the concentration increases, the Relative fluorescence unit (RFU) also increases.

Docking and molecular dynamics studies

The concept behind docking was to assess the potential interaction between the transitmycin Fig. 10a or its derivative molecules and various DNA/Protein targets of interest. Through docking studies, we aimed to validate the anticipated interactions, even though comprehensive molecular dynamics studies were restricted, particularly for the entire transitmycin or its derivatives. Nevertheless, the chromophore part Fig. 10b molecular dynamics dynamics displayed enhanced stability, indicating promising outcomes in our research

We performed docking and molecular docking experiments with a specific target and three ligands: R1, R2, and R3. Our analysis showed that 1MNV displayed favorable interactions with R2, whereas 3PKE exhibited superior binding with R3 Fig. 10c. The docking score data is presented in Table 4.

Docking Score: docking scores were determined using the knowledge-based iterative scoring functions ITScorePP or ITScorePR. A more negative docking score implies a higher likelihood of a binding model. However, it's important to note that the score doesn't represent the true binding affinity, as it hasn't been calibrated against experimental data.

Confidence Score: To gauge the likelihood of binding between two molecules, we introduced a confidence score based on docking scores. The formula for the confidence score is:

Confidence_score=1.01.0+e0.02×(Docking_Score+150)Confidence_score=1.0+e0.02×(Docking_Score+150)1.0

- In this context, when the confidence score surpasses 0.7, it suggests a high probability of
- binding. Scores between 0.5 and 0.7 indicate a possible binding, whereas scores below 0.5
- imply an unlikely binding.
- Ligand RMSD: Ligand RMSD values were computed by comparing ligands in the docking
- models with the input or modelled structures.
- **Table 4**. The docking score data of specific target (1MNV, 3PKE, 1MO3, 3IU8) and three
- 566 ligands: R1, R2, and R3

Name of the Molecule	Docking Score	Confidence Score	Ligand RMSD (A)
1MNV with R1	-489.71	0.9989	22.52
1MNV with R2	-518.80	0.9994	17.61
1MNV with R3	-532.55	0.9995	25.15
1MO3 with R1	-397.33	0.9929	83.36
1MO3 with R2	-424.84	0.9959	83.95
1MO3 with R3	-420.99	0.9956	83.36
3PKE with R1	-391.53	0.9921	52.95
3PKE with R2	-493.89	0.9990	50.96
3PKE with R3	-503.74	0.9992	57.70
3IU8 with R1	-337.77	0.9771	37.59
3IU8 with R2	-418.79	0.9954	47.58
3IU8 with R3	-437.87	0.9969	50.75

We conducted Molecular Dynamics (MD) simulations for the complex 1MNV with R2 and R3. Unfortunately, MD simulations for R2 and R3 couldn't be performed due to the large size of their peptide side chains, preventing accommodation into the minor groove of DNA (1MNV). However, we successfully carried out simulations with the chromophores of R2 and R3. The RMSD of the residues remained within acceptable limits during these simulations.

Additionally, MD simulations were conducted for the complex 3PKE with R3. Similar challenges were encountered with the peptide side chains, leading to simulations being performed with the chromophore, as illustrated in Figure 10b. The RMSD values plotted against residues are presented in Figure 10e.

The results of the MD simulations indicate the stability of the protein backbone throughout the simulation period. However, it is noteworthy that the simulations faced computational challenges, primarily due to the size of the peptide side chains. Despite these difficulties, the obtained data provides valuable insights into the behavior of the complexes during the simulations.




Fig 10. a) Transitmycin structure b) Chromophore part of transitmycin or its derivatives, c) 1 MNV R2 Docking Pose d) 3PKE with R3 Docking pose e) RMSD values of Residues during the simulation Plot (3PKE with R3).

Methods

Characterization and taxonomy of Streptomyces sp. R2

Micromorphology of potential *Streptomyces* sp. R2 was studied by adopting Transplantation Embedding Technique [72]. Briefly, a rectangular trough was dug out of an ISP2 agar plate using sterile knife. Then the spores of *Streptomyces* strain were inoculated on the edges of the trough under aseptic condition. A sterile cover-slip was placed over the agar, touching the inoculated area on the ISP2 agar plate. The plate was incubated at 28°C for 7-14 days. The cover-slip was aseptically removed using sterile forceps and placed over clean microscopic slide fixing the same using cellophane tape. Micromorphology of *Streptomyces* sp. R2 was observed under bright field microscope (Olympus) under 10x and 40x magnifications. Spore structure and spore surface morphology were recorded using a scanning electron microscope (JEOL model JSM5600LV). Media and procedures used for determination of cultural characteristics and carbon and nitrogen source utilization were those described originally by Shirling and Gottileb [24]. Effect of pH, temperature, NaCl concentration and anaerobic condition were studied using modified ISP2 medium. Antibiotic susceptibility pattern was determined by disc diffusion method using standard antibiotic discs (Hi media) following the standard protocol [73]. Biomass for cell wall analysis was prepared by growing Streptomyces sp. R2 in shake flasks (120 rpm) containing ISP2 broth at 28 °C for 5 days. Amino acid and sugar content analyses of whole cell hydrolysates were performed according to the original procedure described by Staneck and Roberts [74].

Molecular characterization and phylogenetic analysis

Streptomyces sp. R2 was grown in 50 ml of ISP2 broth at 28°C for 48 h. The genomic DNA was extracted using Chromous genomic DNA isolation kit. Polymerase chain reaction (PCR) was performed for the amplification of 16S rRNA gene using the primers 5' – AGAGTRTGATCMTYGCTWAC – 3' and 5' – CGYTAMCTTWTTACGRCT – 3' on a ABI12720 thermal cycler (Applied Biosystems). The conditions used for thermal cycling were as follows: initial denaturation at 94°C for 4 min, followed by 35 cycles consisting of denaturation at 94°C for 30 sec, primer annealing at 55°C for 30 sec and primer extension at 72°C for 2 min, followed by a final extension at 72°C for 5 min. The amplified 16s rRNA gene fragment (~ 1.4 kb) was separated by agarose gel electrophoresis and the purified fragment was used for sequencing in an ABI3130 genetic analyser. The nearly complete 16s rRNA gene sequence of strain R2 (1400 nt) was subjected to BLAST comparison against the 16s rRNA sequences given in GenBank/DDBJ/EMBL databases.

626 Phylogenetic analysis was performed using CLUSTAL-W and MEGA version 3.1.

Evolutionary distances (Kimura's two parameter model) [75] and clustering were calculated

employing the neighbour-joining method. The topology of phylogenetic tree was evaluated

by the bootstrap re-sampling method with 1000 replicates.

Production of Transitmycin

627

628

629

630

631

645

646

- Hundred microliters of *Streptomyces* sp. R2 spore suspension was transferred into 10 YEME
- agar plates and spread using sterile L- rods. The plates were incubated at 28°C for 10 days.
- After every 24 hours of fermentation, the mycelial growth was scrapped out and the crude
- pigment secreted into the agar medium was extracted using equal volume (1:1) of different
- organic solvents such as n-hexane, dichloromethane, chloroform, ethyl acetate and methanol
- for 24 hours. The solvent portion was collected and dried at 40°C using Concentrator plus
- 638 (Eppendorf) [76]. Anti TB activity of crude extracts were tested against M. tuberculosis
- 639 H37Rv at 100µg concentration adopting LRP assay [77].
- 640 Streptomyces sp. R2 was cultured for 10 days at 28°C on YEME agar plates (2000 ml of
- medium in 100 petriplates of 90 mm diameter) to produce the culture extract in bulk. After
- 642 the incubation period, the cell material was aseptically removed and discarded after
- autoclaving. The yellow pigmented antibiotic containing agar medium was cut in to pieces
- and extracted twice with equal volume (1:1 ratio) of ethyl acetate for 24 hours.

Purification of transitmycin

- Transitmycin was purified by preparative thin layer chromatography (TLC) using Merck
- silica gel 60 (GF254) pre coated aluminium (6x8 cm size) plates. The extract was separated
- using different solvents in different proportions. After running, the 200 sheets were kept at
- 650 room temperature for complete drying of the plate. Spots on TLC were detected through
- naked eye as well as under UV light (254 and 365 nm). After drying, three major yellow
- colour spots (R1, R2 and R3) were scrapped, mixed with ethyl acetate and filtered using a
- 653 funnel fitted with Whatman filter paper. Ethyl acetate was evaporated to dryness under
- obtain the compounds as dry amorphous powder. (Supplementary Fig. S2).
- All three compounds were tested against M. tuberculosis H37Rv at 100 µg
- concentration by LRP assay. All three compounds from the ethyl acetate extract was purified
- 657 using column chromatography packed with neutral alumina using a gradient of 1%
- 658 methanol/chloroform mixture (CH₃OH/ CHCl₃) as the eluent. Fractions were collected and

concentrated under vacuum to obtain pure transitmycin. The product was visualized in a silica gel coated TLC sheet (Supplementary Fig. S2 and S3).

The compound R1 (named as transitmycin) that showed maximum activity was taken for characterization and other studies testing its biological activity. Purity of transitmycin (Fig. 2c). was analysed by HPLC using Shimadzu (Japan) RID-10A gradient high-performance liquid chromatographic instrument, equipped with two LC-20AD pumps controlled by a CBM-10 inter-face module. Refractive index Detector RID 10A (Shimadzu) was used for the peak. Analysis was performed on a Luna 5u C₁₈ (2) reversed-phase column, 100 (150X4.6mm). The analytical parameters were selected after screening a number of solvent systems and gradient profiles. Separation was achieved using a two-pump gradient program for pump A (0.1% Acetic acid in CH₃CN) and pump B (0.1% Acetic acid in H₂O) in a linear gradient of acetonitrile and water from 0:100 to 65:35 in 65 minutes at a flow rate of 2 ml/min. Detection was done at 254 nm, the absorption maxima close to that of majority of the compounds. Injection size for sample was 20 μl. Column temperature was 30°C. (Supplementary Fig. S4 and S5).

Characterization and structure elucidation

Colour and consistency of the purified antibiotic was visually observed. Solubility was tested in water, methanol, acetone, ethyl acetate, diethyl ether, dichloromethane, chloroform, and n-hexane by dissolving 1 mg of purified antibiotic. Optical rotations were measured with a Autopol IV Automatic polarimeter, and the $[\alpha]_D$ values are given in deg cm² g⁻¹. Melting point was analysed using Mettler Toledo Model FP62 [78]. Ultraviolet (UV) spectrum was determined using Shimadzu UV-1700 series. One milligram of sample was dissolved in 10ml of methanol and the spectra were recorded at wavelength between 190 – 900 nm. The Infrared (IR) spectrum of the purified antibiotic was determined on Perklin Elmer Spectrum One FT-IR. The spectrum was obtained using potassium bromide (KBr) pellet technique in the range of 450 to 4000 cm⁻¹ at a resolution of 1.0 cm⁻¹. Potassium bromide (AR grade) was dried under vacuum at 100°C and 100 mg of KBr with 1mg of purified antibiotic was used to prepare KBr pellet. The spectrum was plotted as intensity versus wave number [79]. ¹H and ¹³C NMR spectra were recorded on a Bruker Advance 500 NMR spectrometer in CDCl₃ with TMS as internal Standard and with chemical shifts (δ) reported in ppm. Two-dimensional ${}^{1}H-{}^{1}H$ COSY, DQF-COSY, NOESY, ROESY, ¹H-¹³C HSQC, HMBC, and spectra were recorded on a Bruker Advance 500 NMR spectrometer. MALDI-TOF MS analyses were performed using an Applied Biosystems

- 693 ABI4700 TOF mass spectrometer in reflector mode with an accelerating voltage of 20 kV.
- 694 HRESIMS were measured on a Q-TOF micro mass spectrometer (Waters USA) in positive
- 695 ion mode with methanol as solvent. QTOF- MS was recorded on an Agilent 6520-QTOF
- 696 LCMS having an ESI source in positive mode.

HPLC Analysis of L-FDAA Derivatives of Transitmycin

Transitmycin (3.0 mg) was dissolved in 1 ml of 6NHCl and heated in a sealed glass tube at 110°C for 24 h. After removing the solvents, the hydrolysate mixture (3 mg) and the amino acid standards (0.5 mg) were separately dissolved in 0.1 mL of water and treated with 0.2 mL of 1% 1-fluoro-2,4-dinitrophenyl-5-L-alaninamide (FDAA) (Marfey's reagent) in acetone (10 mg/mL in acetone) and 0.04 mL of 1.0 M sodium bicarbonate. The vials were heated at 50°C for 90 min, and the contents after cooling at room temperature were neutralized with 1N HCl. After degassing, an aliquot of the FDAA derivative was diluted in CH₃CN, Water (1:1) and analysed by reversed phase HPLC column Luna 5u C₁₈ (2) 100 (150X4.6mm) and a linear gradient of acetonitrile and water containing 0.05% trifluoroacetic acid from 10:90 to 50:50 in 20 min and then isocratic. The flow rate was adjusted to 1 mL/min and the absorbance detection was at 340 nm. The chromatogram was compared with those of amino acid standards treated in the same conditions [60-61].

LC-MS Analysis of L-FDAA Derivatives of Transitmycin

The analysis of the L- and D-FDLA derivatives of Transitmycin was performed on a Waters Acquity UPLC coupled with a Thermo LCQ Deca XP MAX. QTOF- MS was recorded on an Agilent 6520-QTOF LCMS having a ESI source in Positive mode and employing a linear gradient of from 25% to 70% CH₃CN in 0.01 M formic acid at 0.5 mL/min over 60 min [62-64].

- **Transitmycin (R1).** R1 was obtained as an orange red solid; $[\alpha]_D^{25}$ -106 ° (c 0.2, MeOH);
- 720 UV (MeOH) λ_{max} (log ϵ) 214 (3.07), 240 (2.30), 425 (1.44), 442 (1.51) nm; CD
- 721 [(MeOH),(mdeg)] $\lambda_{\text{max}}(\Delta \epsilon)$ 195 (+11.1), 210 (-21.0), 242 (+4.7) nm; IR (KBr), ν_{max} 3435,
- 722 2958, 2924, 2853, 1745, 1642, 1524, 1465, 1379, 1194, 1099, 1059 cm⁻¹; HRESI-MS
- 723 (pos.ions): m/z 1270.7069 [M+2H]⁺,1291.8449 [M+Na]⁺, 1307.9286 [M+K]⁺657.3119
- $[M+2H]^{+2}$; MALDI-TOF-MS (pos.ions):m/z 1293.07095 $[M+Na+2H]^{+}$, 1309.93062

- 725 [M+K]⁺ MALDI-TOF-MS (neg.ions) 1269.33344 [M-H]⁻ ¹HNMR, ¹³NMR and 2DNMR
- details (Supplementary Fig. S14-52, S-Table 5).

735

743

744

- **Compound (R2).** R2 was obtained as a red solid; $[\alpha]_D^{25}$: -24° (c 0.2, MeOH); UV(MeOH) λ
- 729 max, (log ε) 205(1.25),240(0.63),425 (0.39), 442 (0.42) nm; CD [MeOH, (mdeg)] λ_{max} , (Δε)
- 730 195 (+8.8), 210 (-22.0), 240 (+4.3) nm;IR (KBr), v_{max}3436, 2961, 2924, 2853, 1744, 1650,
- 731 1565, 1415, 1204, 1140, 1045, 1019 cm⁻¹; HRESI-MS (pos. ions) :1277.8245 [M +
- 732 Na]+1293.8735 [M + K]+m/z 650.3413 [M+2H]+2; MALDI-TOF-MS m/z (pos.ions)
- 733 1278.95175 [M+Na+H]⁺; MALDI-TOF-MS (neg.ions) m/z 1255.38052 [M-H]⁻, ¹HNMR,
- 734 ¹³NMR and 2D NMR details (Supplementary Fig. S53-63).
- **Compound (R3):** R3 was obtained as orange solid; $[\alpha]_D^{25}$:-27 ° (c 0.2, MeOH); UV
- 737 (MeOH) λ_{max} (log ϵ) 206 (1.90), 240 (0.69) 424 (0.191), 442.2 (0.19) nm; CD [MeOH,
- 738 (mdeg)] λ_{max} ($\Delta \epsilon$) 195 (+24.0), 210 (-21.5), 241 (+1.7) nm; IR (KBr), ν_{max} 3415, 2957, 2924,
- 739 2853, 1745, 1642, 1583, 1464, 1384, 1193, 1093, 1078 cm⁻¹; HRESI-MS
- 740 (pos.ions):1271.7159 [M +H] $^+$ m/z1277.6149 [M-OH+Na] $^+$; MALDI-TOF-MS (pos.ions)
- 741 m/z 1294.5888 [M + Na]⁺ MALDI-TOF-MS (neg. ions) m/z 1268.48582 [M-H]⁻, ¹HNMR,
- 742 ^{13C}NMR and 2D NMR details, (Supplementary Fig. S64-69).

Determination of anti TB and anti-HIV activity

- 745 Anti-TB activity was determined by adopting Luciferase Reporter Phage (LRP) assay
- against the standard laboratory strain, Mycobacterium tuberculosis H₃₇Rv, and 97 clinical M.
- 747 *tuberculosis* isolates including drug sensitive and cultures exhibiting different drug resistant
- 748 patterns. Different concentrations $(5 50 \mu g/ml)$ of purified antibiotic transitmycin were
- 749 prepared using 10% dimethyl sulfoxide (DMSO). About 50µl of antibiotic solution was
- 750 added to 350 μl of glycerol 7H9 broth in cryo vials. Effect of DMSO was also tested by
- 751 adding 50 µl of 10% DMSO instead of the antibiotic. Mycobacterial cell suspension
- 752 equivalent of 2 McFarland units was prepared from log phase culture and 100 µl of the same
- was added to all the vials before incubating at 37°C for 72 hours. After incubation, 50 µl of
- high titre luciferase reporter phage phAE129 and 40 µl of 0.1M CaCl2 were added to test
- and control vials. All the vials were incubated at 37°C for 4 hours. After incubation 100 µl
- of suspension from each vial was transferred to a luminometer cuvette. 100 µL of D-
- 757 luciferin was added and relative light unit (RLU) was measured in a luminometer [77].

758 Percentage of inhibition was calculated using the RLU of control and test and MIC was

determined. [81,82]

759

760

761

762

Activity against M. tuberculosis biofilm

- 763 Cell suspensions of *M. tuberculosis* H37Rv were prepared using 7H9 broth. Biofilms of *M.*
- 764 tuberculosis were developed on 6 well tissue culture plates by adding 2 ml of Sautons
- 765 medium (without Tween 80) and inoculating 20 μ L of saturated planktonic culture of M.
- 766 tuberculosis H₃₇Rv. The plate was wrapped with parafilm and incubated without shaking at
- 767 37°C in humidified conditions for 7 to 14 days. The plate was observed regularly after 7
- days for biofilm formation by *M. tuberculosis* which can be visibly seen. When the biofilm
- 769 was formed, 10 μg/ml of transitmycin was added to the transitmycin test wells leaving the
- controls and considered as zero day. The viable counts of tubercle bacilli were determined
- from the wells on zero day, 4th day and after 5 weeks and expressed in cfu/ml [80].

772 Anti-HIV activity

- 773 Viruses: HIV-1 viruses belonging to subtypes A, B, C, D, E and A/C (Subtype A:
- 92RW020, Subtype B: JR-FL, Subtype C: 92BR025, Subtype D: 92UG001, Subtype E:
- 92TH021 and Subtype A/C: 92RW009), were obtained from the NIH AIDS Repository
- (Germantown, MD, USA). Clinical isolates of HIV-1 were produced in our laboratory by
- co-culture of HIV-infected peripheral blood mononuclear cells (PBMC) with activated
- donor PBMC.

779

780

Testing for anti-HIV activity

- 781 Anti-HIV activity of Transitmycin was determined using the HIV-1 gag p24 inhibition
- assay. Initially, testing was performed on a lab-adapted HIV-1 subtype B isolate, HIV-1
- 783 IIIB. Donor PBMC were obtained from healthy volunteers after obtaining the approval of
- 784 the Institutional Ethics Committee of the National Institute for Research in Tuberculosis as
- well as the informed consent of the participants. Donor PBMC were stimulated with PHA
- 786 (Phytohemeagglutinin) for 72 hours and incubated with 100 TCID₅₀ of the virus per 1 x 10⁶
- cells for 4 h at 37°C. The cells were washed to remove the un-adsorbed virus and plated at a
- concentration of 10,000 cells/well in a 96-well tissue culture plate. Varying concentrations
- 789 of Transitmycin (0.01μg/ml, 0.1μg/ml, 1.0μg/ml and 5.0μg/ml) were added to triplicate

- wells. Control cultures were set up without the addition of the compound. AZT was used as
- 791 the reference compound. Cultures were maintained for 7 days at 37°C in a CO₂ incubator.
- On day 7, HIV-1 gag p24 antigen production was determined as an indirect measure of viral
- 793 replication in the culture supernatants using the Alliance HIV-1 p24 ELISA kit (Perkin
- 794 Elmer, USA).

810

819

820

795 Testing of Transitmycin against different HIV-1 subtypes

- 796 Anti-viral activity of Transitmycin was also tested on primary HIV-1 isolates belonging to
- 797 different subtypes Subtype A: 92RW020, Subtype B: JR-FL, Subtype C: 92BR025,
- 798 Subtype D: 92UG001, Subtype E: 92TH021 and Subtype A/C: 92RW009, as well as a
- 799 Nevirapine resistant and AZT resistant strain, using the method described above. The
- activity of Transitmycin on different viruses was determined by measuring HIV-1 p24
- antigen in 7-day culture supernatants. The IC₅₀value (concentration of compound required to
- 802 inhibit 50% of virus replication) of Transitmysin for the different HIV- 1 subtypes was
- calculated by fitting a dose response curve using a non-linear regression analysis to generate
- a sigmoidal three parameter dose response curve (GraphPad Prism, version 6).

Activity against clinical strains of HIV

- 806 Anti-viral activity of Transitmycin was further evaluated on 20 clinical isolates of HIV-1
- 807 obtained by co-culture of patient PBMC with PHA-stimulated donor PBMC in the
- laboratory. For this analysis, only three concentrations (0.01 µg/ml, 0.1 µg/ml and 1µg/ml)
- of transitmycin was used based on the results of the above experiment.

DNA binding and Fluorescence assay

- 811 0.5 μg/ml, 1 μg/ml, 2 μg/ml and 5 μg/ml of R1, R2 and R3 were separately added to 100 μl
- 812 of PBS in triplicates in 96 well plate. Mycobacterium tuberculosis genomic DNA was
- extracted and 200 ng of DNA is added to each test wells. DNA was not added to the control
- wells of R1, R2 and R3. For the positive control, 0.5 µg/ml of Ethidium bromide is taken in
- PBS and 200 ng of DNA is added to it. After 15 mins, the plate is read in Multimode plate
- 816 reader, Spinco Biotech, with excitation 546 nm and emission 595 nm. The relative
- 817 fluorescence unit is recorded. Average of RFU for each concentration of R1, R2 and R3 was
- 818 taken and plotted as graph.

Conclusion:

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

845

Globally, the general public has latent or active tuberculosis, and this is expected to increase in the future, causing the medical system a major challenge. The need of the hour is to identify novel antibiotics to support the current regimens with reduced side effects, duration and cost of treatment. Transitmycin is a novel antibiotic isolated from a novel *Streptomyces* sp. MTCC from the coral reef soil from Rameshwaram waters in India. It has the unique property of killing latent and active forms of TB bacilli irrespective of the resistance they have towards major antiTB drugs and also sterilising the different resistant and recombinant clades of standard and clinical HIV virus. When brought into the market for human use, transitmycin can strategize treating TB and HIV simultaneously, which could be a major breakthrough, none the less. Of course, preclinical trials and toxicity studies need to be performed before it can be tested on human volunteers which will require sufficient resources. Countries which are burdened with this dual ailment may have to take considerable interest in this direction. Structural medications to the parent compound can further improve its activity.

Acknowledgement

- 839 Professor Balasubramanian Kalpattu Kuppusami, INSA Senior Scientist, Department of
- 840 Chemistry, IIT Madras Chennai 600 036, India and Professor Krishna Kumari Gadepalli
- Narasi, Department of Medicinal Chemistry, Sri Ramachandra University, Chennai 600 116,
- 842 India, acknowledged for discussion of structure elucidation of Transitmycin. Technical
- assistance of Dr. S. Balaji and Dr. A. S. Shainaba of National Institute for Research in
- 844 Tuberculosis is acknowledged in fine tuning and uploading the manuscript.

Supplementary materials

- 846 The comprehensive characterization of the anticipated products have been subjected
- through UV/Vis, IR, CD, CHNS analyses, whilst, followed by ¹H-NMR ¹³C-NMR, ¹H-¹H
- 848 COSY, ¹H-¹H DOF-COSY, ¹H-¹³C HMBC, and ¹H-¹³C HSQC, ¹H-¹H TOCSY, ¹H-¹H
- NOESY, ¹H-¹H NOESY 2D NMR spectra and MALDI-TOF-MS, HR-ESIMS, HR-LCMS,
- 850 ESI-MS, QTRAP LC-MS/MS, RP-HPLC and LCMS analyses respectively. The following
- L-FDAA derivatives of R1, R2, R3 spectral information on all compounds of this article can
- be found in the online version.

Funding Received for this study

- Potential Tuberculosis Drugs from Marine Actinomycetes, Funded by Department of Science and Technology, New Delhi (November, 2007 to November, 2009).
- 858 2) Study to evaluate the baseline anti TB and anti-HIV properties of novel antibiotic
- transitmycin (Tr) isolated from novel *Streptomyces* Sp. R2 funded by Indian Council of
- 860 medical Research (2009-2012).
- 861 3) Purity and in vitro efficacy studies on transitmycin funded by Indian Council of Medical
- 862 Research (2015-2016).

853

854

855

863

864

Authors' individual contributions

- 865 Vanaja Kumar Principal Investigator, planning, supervision, coordination and data
- 866 compilation, manuscript writing and editing.
- 867 Balagurunthan Ramasamy–Facilitating Growing of producer strain, coordination in crude
- extract preparation as lab head.
- 869 Mukesh Doble Purification of compound from crude extract, structure analysis and
- 870 chemical characterisation and report preparation as lab head.
- 871 Gandarvakottai Senthilkumar Arumugam Isolation, purification, characterization,
- 872 complete structural elucidation and a key role in Innovation Of Transitmycin drug discovery
- 873 development and manuscript writing and editing.
- 874 Kannan Damodharan Isolation, purification, characterization, structural elucidation of
- 875 Transitmycin compounds and final manuscript drafting.
- 876 Radhakrishnan Manikkam- Isolation and characterisation of producer strain, biological and
- 877 biochemical characterisation, testing biological activities, data compilation, manuscript
- 878 writing.
- Hanna Luke Elizabeth Testing crude extract and purified compound on HIV standard and
- 880 clinical clades. Preparation of write up.
- 881 Suresh Ganesan Isolation, purification, characterization, structural elucidation of
- 882 Transitmycin compounds and final manuscript drafting
- 883 Azger Dusthackeer- Testing biological activities against latent bacilli and biofilms,
- preparing the write up.
- Precilla Lucia Laboratory work for testing the compound on HIV clades.

- 886 Shainaba A Saadhali- Testing biological activities against latent bacilli and biofilms,
- preparing the write up.
- 888 Shanthi John laboratory work with respect to growing the producer strain and preparation
- 889 of crude extract.
- 890 Poongothai Eswaran laboratory work with respect to growing the producer strain and
- preparation of crude extract.
- 892 Selvakumar Nagamiah– supervision of laboratory work on testing biological activities,
- 893 editing manuscript.
- 894 Soumya Swaminathan Facilitating coordinated activity for fund release, conduct of
- 895 experiments against HIV clades as Head of the laboratory and the Institute.
- 896 Jaleel UCA-Provided the overall conceptualization of theoretical study, and offered
- 897 guidance throughout the research process and reviewed and edited the manuscript to ensure
- 898 clarity, consistency, and scientific accuracy.
- 899 Rakhila M-Conducted the data analysis, molecular docking simulations, and statistical
- 900 interpretation of the results and edited the manuscript to ensure clarity, consistency, and
- 901 scientific accuracy.
- 902 Ayisha Safeeda- Conducted the data analysis, molecular docking simulations, and statistical
- 903 interpretation of the results and edited the manuscript to ensure clarity, consistency, and
- 904 scientific accuracy.

911

912

913

- Satheesh S -was responsible for creating and editing the figures and tables that visually
- 906 represented the key findings.

908 Additional Information

- 909 Competing Interests
- 910 The authors declare no competing interests.

Figure Legends

- **Fig. 1.** Representative HPLC chromatogram of crude and isolated samples R1, R2 and R3. **a**
- 915 RP HPLC of Chromatogram of crude extract of *Streptomyces* sp. R2. **b** RP HPLC analysis
- 916 of mixture of R1, R2, R3. c RP HPLC of Chromatogram of pure Transitmycin R1. d
- 917 Transitmycin R1 obtained after column chromatographic purification. e UV-Vis spectra of
- 918 Transitmycin R1, R2 and R3. f IR Spectrum of Transitmycin R1.

- 919 Fig. 2 Notable characteristic ¹H NMR spectra of different proline units of Transitmycin as a
- 920 R1 (4-oxoproline). **b** R2 (proline) and **c** R3 (4-OH proline). **d** Comparative studies for ¹H
- 921 NMR (500 MHz, CDCl₃) chemical shift value of NH containing amino acid residue and
- 922 chromophore motifs of Transitmycin (R1), R2 and R3.
- 923 Fig. 3. a Key ¹H-¹H COSY correlation of Transitmycin (R1). b Key ¹H-¹H TOCSY
- orrelation of Transitmycin (R1). c Key ¹H-¹³C HMBC connectivity for Transitmycin (R1).
- 925 c ¹H-¹H ROESY correlation of Transitmycin (R1). d Chemical structure of isolated
- 926 compounds Transitmycin (R1). e R2. f R3.
- 927 Fig. 4 a-m. Comparative analysis of MALDI-TOF-MS for molecular ion peak of
- 928 Transitmycin (R1), R2, R3. a R1 (Simulated). b R2 (Simulated). c R3 (Simulated). d R1
- 929 (Measured, positive mode. e R2 (Measured, Positive mode). f R3 (Measured, Positive
- 930 mode). g R1 (Measured, Negative mode). h R2 (Measured, Negative mode). i R3
- 931 (Measured, Negative mode), MALDI-TOF-MS spectra of crude extract of *Streptomyces* sp.
- R2. j positive mode. k negative mode l Comparative analysis for HR-ESI-MS and MALDI-
- 933 TOF-MS of Transitmycin (R1), R2 and R3 on various batches. **m** Characteristic retention
- 934 factor (R_f) value and corresponding HR-ESI-MS data of purified compounds (Transitmycin
- 935 (R1), R2 and R3).
- 936 Fig. 5. a Mass spectral fragmentation of Transitmycin (R1) obtained by MALDI-TOF-MS,
- 937 **b** MALDI-TOF-MS spectrum of Transitmycin (R1). **c** Mass spectral fragmentation of
- 938 Transitmycin (R1) obtained by MALDI-TOF-MS, 211- β-Ring-Val-Oxo-Pro, 233- α -Ring-
- 939 Val-Pro, 294-β-Ring-Oxo-Pro-Sar-NMeVal, 295-Chromophore, 297- β-Ring-Thr-Val-Oxo-
- 940 Pro, 357-α-Ring-Val-Pro-Sar-MeVal, 371-β-Ring-Val-Oxo-Pro-Sar-MeVal, 412-β-Ring-
- 941 Val-Oxo-Pro-Sar-NMeVal, 412-α-Ring-Val-Pro-Sar-NMeVal+859 (Y ion), 495-β-Ring-
- 942 Thr-Val-Oxo-Pro-Sar-NMeVal, 496-α-Ring-Thr-Val-Pro-Sar-NMeVal, 464 α Ring-Thr-
- 943 Val-Oxo-Pro-Sar-NMeVal, 746-Y-113 (MeVal), 747- α-Ring-Val-Pro-Sar-NMeVal+Y-
- 944 MeVal+545.6, 495= β-Ring-Thr-Val-Oxo-Pro-Sar-NMeVal, 495-371=124-23=101 MeVal
- 945 (β-Ring-Thr-Val-Oxo-Pro-Sar), 371(β-Ring-Thr-Val-Oxo-Pro-Sar), 294 (β-Ring-Thr-Val-
- 946 Oxo-Pro).

- 948 Fig. 6. a HPLC data analysis for L-FDAA derivatives to hydrolysates of Transitmycin R1
- and standard amino acids. **b** Graphical representation for RP-HPLC chromatogram of L-

950 FDAA (Marfey's) derivatives of hydrosylated Transitmycin (R1). c HR-LCMS data analysis

951 for L-FDAA derivatives to hydrolysates of Transitmycin R1 and standard amino acids.

- 953 Fig. 7. MIC of Transitmycin in micrograms per millilitre for Mycobacterium tuberculosis
- 954 isolates susceptible to anti-TB drugs (n=49) and drug resistant to one or more anti-TB drugs
- 955 (n=48) as determined by LRP assay. Sensitive strains are represented in blue colour and
- 956 resistant strains are represented in brown colour.
- **Fig. 8 a** Activity of Transitmycin against different HIV-1 clades. Various concentrations of
- 959 Transitmycin were tested using 100 TCID₅₀ of virus belonging to 6 different HIV-1 clades as
- 960 well as two drug-resistant strains. Each concentration was tested in triplicate on all the
- 961 indicated viruses and mean \pm SEM values are shown in the graph. Log₁₀ -2 in the figure
- 962 equals 0.01 μ g/ml, Log₁₀ -1 equals 0.1 μ g/ml, Log₁₀ 0 equals 1 μ g/ml and Log₁₀ 1 equals 10
- 963 µg/ml. **b** Activity of Transitmycin on clinical isolates obtained from HIV-1 infected
- 964 individuals. Three concentrations of Transitmycin and two concentrations of AZT were
- 965 tested against 20 clinical isolates and mean + SD values are shown on the graph. This
- experiment was performed on two different occasions.
- 968 Fig. 9 a) R1, b) R2 and c) R3 binds with the DNA and emit fluorescence in a dose
- dependent manner. The concentrations of R1, R2 and R3 tested were 0.5 µg/ml, 1 µg/ml, 2
- 970 μg/ml and 5 μg/ml. As the concentration increases, the Relative fluorescence unit (RFU)
- 971 also increases.

952

957

967

972

976

- 973 Fig 10. a) Transitmycin structure b) Chromophore part of transitmycin or its derivatives,
- 974 c) 1MNV R2 Docking Pose d) 3PKE with R3 Docking pose e) RMSD values of Residues
- 975 during the simulation Plot (3PKE with R3).
- 977 Table Legends
- 979 **Table 1**. ¹H NMR (500 MHz, CDCl₃)/¹³C NMR (125 MHz, CDCl₃) and 2D NMR (500
- 980 MHz, CDCl₃) correlation spectral data of Transitmycin (R1) ¹ H–¹ H COSY, ¹H–¹H TOCSY
- 981 ¹H-¹³C HMBC, ¹H-¹H ROESY
- **Table 2.** Physico-chemical properties of Transitmycin.

- **Table 3.** Activity of transitmycin on biofilm formation.
- **Table 4.** The docking score data of specific target (1MNV, 3PKE, 1MO3, 3IU8) and three
- 985 ligands: R1, R2, and R3
- 986 References
- 9871. Abdelmohsen UR, Potential of marine natural products against drug-resistant fungal, viral,
- 988 and parasitic infections. *Lancet Infect. Dis.* 2017;17: e30–e41.
- 2. Quan D, et al. New tuberculosis drug leads from naturally occurring compounds. *Int. J. Infect. Dis.017*;56:212-220.
- 9913. Shin HJ, Kwon JS. Treatment of Drug Susceptible Pulmonary Tuberculosis. *Tuberc. Respir*.
- 992 *Dis.2015*; 78:161-167.
- 4. <u>Tran</u> T, et al. Sansanmycin natural product analogues as potent and selective antimycobacterials that inhibit lipid I biosynthesis. *Nature Commun.* 2017; 8:14414.
- 5. Sotgiu G. *et al.* Tuberculosis Treatment and Drug Regimens. Cold Spring Harb Perspect Med 2015;5: a017822.
- 9976. Igarashi M, et al. New antituberculous drugs derived from natural products: current
- 998 perspectives and issues in antituberculous drug development. J. Antibiot. 2018;71:15–25.
- 9997. UNAIDS Report, (2017)
- 10008. Schader SM, Wainberg MA. Insights into HIV-1 pathogenesis through drug discovery: 30
- years of basic research and concerns for the future. *HIV AIDS Rev.* 2011; 10:91–98.
- 10029. Parveen M, et al. Anti-HIV Drug Discovery Struggle: From Natural Products to Drug
- 1003 Prototypes. In Natural Products in Clinical Trials. Publisher: Bentham Science Publishers
- 1004 (2018).
- 100510. Huang T, Lin S, Microbial Natural Products: A Promising Source for Drug Discovery. J.
- 1006 Appl. Microbiol. Biochem. 2017;1:5.
- 100711. Barka EA, et al. Taxonomy, physiology, and natural products of Actinobacteria. Microbiol.
- 1008 Mol. Biol. Rev. 2016: 80; 1-43.
- 100912. Berdy J, Thoughts and facts about antibiotics: Where we are now and where we are heading.
- 1010 J. Antibiot.2012;65:385-395.
- 13. Velho-Pereira, SKamat, NM. Actinobacteriological research in India. *Indian J. Exp. Biol.* 2013; 51:573–596.
 - 14. Balagurunathan R, et al. Extremophilic and extremotolerantActinomycetes: Distribution and Importance. In: Recent Trends in Microbial Diversity and Bioprospecting. Westville Publishing House, New Delhi (ISBN: 978-93-83491-14-8); 2014: pp. 114-128.

- 1013
- 15. <u>Dhakal</u> D, et al. Marine Rare Actinobacteria: Isolation, Characterization, and Strategies for Harnessing Bioactive Compounds. *Front Microbiol.* 2017;8;1106.
- 101516. Genilloud O, Actinomycetes: still a source of novel antibiotics. Nat. Prod. Rep. 2017;34:
- 1016 1203-1232.
- 101717. Lam, KS. Discovery of novel metabolites from marine actinomycetes. Curr. Opin.
- 1018 *Microbiol.* 2006:9;245-251.
- 101918. Raveh A, et al. Discovery of potent broad-spectrum antivirals derived from marine
- 1020 actinobacteria. *PLoS ONE*. 2013;8: e82318.
- 102119. Valliappan K, et al. Marine actinobacteria associated with marine organisms and their
- 1022 potentials in producing pharmaceutical natural products. Appl. Microbiol.
- 1023 Biotechnol. 2014:98;7365–7377.
- 102420. Blunt JW, et al. Marine natural products. Nat. Prod. Rep. 2018; 35:8-53.
- 102521. Sarkar S, et al. Enhanced production of antimicrobial compounds by three salt-tolerant
- actinobacterial strains isolated from the Sundarbans in a niche-mimic bioreactor. Mar.
- 1027 Biotechnol.2008;10:518-526.
- 102822. Saha M, et al. Production and purification of a bioactive substance inhibiting multiple drug
- 1029 resistant bacteria and human leukemia cells from a salt-tolerant
- marine Actinobacterium sp. isolated from the Bay of Bengal. Biotechnol. Lett. 2006;
- 1031 28:1083–1088.
- 103223. Tindall BJ, et al. Notes on the characterization of prokaryote strains for taxonomic purposes.
- 1033 Int. J. Syst. Evol. Microbiol. 2010; 60:249e266.
- 103424. Shirling EB, & Gottileb D. Methods for characterization of Streptomyces species. Int. J.
- 1035 Syst. Bacteriol. 16, 313-340 (1966).
- 103625. Nonomura H. Key for classification and identification of 458 species of the *Streptomyces*
- included in ISP. *J. Ferment. Technol. 1974*; 52:78-92.
- 103826. Labeda DP, Shearer MC. Isolation of actinomycetes for biotechnological applications. In
- 1039 Isolation of Biotechnological Organisms from Nature, D.P. Labeda, Ed., 1990;19:1–19,
- 1040 McGraw-Hill, New York, NY, USA.
- 104127. Konstantinidis KT, Tiedje JM. Genomic insights that advance the species definition for
- 1042 prokaryotes. *Proc. Natl. Acad. Sci.* 2005; 102:2567-2572.
- 104328. Stackebrandt E, et al. Report of the ad hoc committee for the reevaluation of the species
- definition in bacteriology. Int. J. Syst. Evol. Microbiol. 2002;52:1043-1047.

- 104529. Gopikrishnan V, et al. Quercetin from marine derived Streptomyces fradiae PE7:
- Taxonomy, fermentation, antifouling activity and characterization. *Environ. Sci. Pollut. Res.*
- 1047 Int. 2016; 23:13832-13842.
- 104830. Pazhanimurugan R, et al. Terpenoid bioactive compound from *Streptomyces rochei* (M32):
- Taxonomy, fermentation and biological activities. World. J. Microbiol. Biotechnol. 2016;31:
- 1050 161.
- 105131. Manteca A, et al. Mycelium differentiation and antibiotic production in submerged cultures
- of Streptomyces coelicolor. Appl. Environ. Microbiol. 2008;74:3877-3886.
- 105332. Shomura T, et al. Studies on actinomycetales producing antibiotics only on agar culture I.
- Screening, taxonomy and morphological productivity relationship of *Streptomyces halstedii*
- 1055 strain SF-1993. J. Antibiot. 1979; 32:427-435.
- 105633. Mayurama HB, et al. A new antibiotic, fumaridmycin. I. Production, biological properties
- and characterization of producer strain. *J. Antibiot.1975*;28:636-647.
- 105834. Ohnishi Y, et al. Structures of Grixazone A and B, A-factor dependent yellow pigments
- produced under phosphate depletion by *Streptomyces griseus*. *J. Antibiot.*2004;57:218-223.
- 106035. Conti F, De Santis P. Conformation of Acitinomycin D. Nature. 1070; 227:191239-1241.
- 106236. Ulrich Hollstein, Actinomycin. Chemistry and Mechanism of Action, Chemical Reviews,
- 1063 1974, 74;6.625-652.

1064

1067

1070

1074

1078

- 106537. AB. Mauger, WA. Thomas, NMR Studies of Actinomycins Varying at the Proline Sites,
- 1066 ORGANIC MAGNETIC RESONANCE, 1981;17:3,1981.
- 106838. Yu C, Tseng YY. NMR study of the solution conformation of actinomycin D. Eur. J.
- 1069 Biochem. 1992; 209:181–187. https://doi.org/10.1111/j.1432-1033.1992.tb17275.x.
- 107139. Shigehiro K, Fusao T. Multiple Binding Modes of Anticancer Drug Actinomycin D:X-ray,
- 1072 Molecular Modeling, and Spectroscopic Studies of d (GAAGCTTC)2-Actinomycin D
- 1073 Complexes and Its Host DNA, *J. Am. Chem. SOC.* 1994;116:41544165.
- 107540. Helmut L, Isabel B, Nobuharu S, Lewis KP, Anthony B. Mauger. Structures of Five
- 1076 Components of the Actinomycin Z Complex from Streptomyces fradiae, Two of Which
- 1077 Contain 4-Chlorothreonine. *J. Nat. Prod.* 2000; *63:352-356*.
- 107941. Jens B, Victoria G, Axel Z, Actinomycins with Altered Threonine Units in the â-
- 1080 Peptidolactone, *J. Nat. Prod.* 2006;69:1153-1157.

- 108242. Bitzer J, Streibel M, Langer, HJ, Grond S. First Y-type actinomycins from Streptomyces
- with divergent structure-activity relationships for antibacterial and cytotoxic properties. Org.
- 1084 Biomol. Chem. 2009; 7:444–450.

1089

1094

1098

1100

1106

1111

1116

1120

- 108643. Lackner H, Bahner I, Shigematsu N, Pannell LK, Mauger, AB. Structures of five
- components of the actinomycin Z complex from Streptomyces fradiae, two of which contain
- 4-chlorothreonine. J. Nat. Prod. 2000; 63:352–356. https://doi.org/10.1021/np990416u.
- 109044. Caixia C, Fuhang S, Qian W, Wael M, Abdel M, HuiGuo, Chengzh F, Weiyuan H,
- Huanqin D Xueting L Na Yang, FengXie, Ke Yu, Ruxian Chen, Lixin Zhang, A marine-
- derived Streptomyces sp. MS449 produces high yield of actinomycin X2 and actinomycin D
- with potent anti-tuberculosis activity. Appl Microbiol Biotechnol. 2012; 95:919–927.
- 109545. Xiaoling W, Jioji Tabudravu Mostafa Ezzat Rateb, Krystal JA, Zhiwei Q, Marcel J, Zixin D,
- 1096 Yi Yband, Hai D, Identification and characterization of the actinomycin G gene cluster in
- 1097 Streptomyces iakyrus. *Mol. BioSyst.* 2013: 9:1286—1289.
- 109946. Xiufang Zhang, Xuewei Ye, Weiyun Chai, Xiao-Yuan Lian, and Zhizhen Zhang, New
- 110147. Metabolites and Bioactive Actinomycins from Marine-Derived Streptomyces sp. ZZ338,
- 1102 Mar. Drugs 2016;14:181.
- 110348. Machushynets, NV, Elsayed, SS, Du C. et al. Discovery of actinomycin L, a new member
- of the actinomycin family of antibiotics. Sci Rep 2022; 12:2813.
- 1105 https://doi.org/10.1038/s41598-022-06736-0.
- 110749. Wang Q, Zhang Y, Wang M. et al. Neo-actinomycins A and B, natural actinomycins
- bearing the 5H-oxazolo[4,5-b] phenoxazine chromophore, from the marine-derived
- 1109 Streptomyces sp. IMB094. Sci Rep. 2017; 7: 3591. https://doi.org/10.1038/s41598-017-
- 1110 03769-8.
- 111250. Qureshi KA, Bholay, AD, Rai PK. et al. Isolation, characterization, anti-MRSA evaluation,
- and in-silico multi-target anti-microbial validations of actinomycin X2 and actinomycin D
- produced by novel Streptomyces smyrnaeus UKAQ_23. Sci Rep. 2021; 11:14539.
- https://doi.org/10.1038/s41598-021-93285-7.
- 111751. Zhang Z, Peng G, Yang G, Xiao CL, Hao XQ (2009) Isolation, purification, identification
- 1118 of structures and study of bioactivity of anti-TB active component 9005B. Chin J Antibiot
- 111934:399-402.
- 112152. Roboz, J Nieves E, Holland JF. McCamish, M, Smith C. Collisional Activation
- 1122 Decomposition of Actinomycins Using Tandem Mass Spectrometry BIOMEDICAL AND
- 1123 ENVIRONMENTAL MASS SPECTROMETRY, 1988;16:67-70.
 - 42

- 112553. Darren T, Michael M, Jonathan M. Curtis R, K. Boyd K, Fragmentation Mechanisms of
- 1126 Protonated Actinomycins and Their Use in Structural Determination of Unknown
- Analogues, JOURNAL OF MASS SPECTROMETRY.1995;30:1111-1125.
- 1128 54. Rebecca H. Wills, Peter BO. Connor Structural Characterization of Actinomycin D
- 1129 Using Multiple Ion Isolation and Electron Induced Dissociation J. Am. Soc. Mass Spectrom.
- 1130 2014; 25:186Y195.
- 1131 55. Benzel J, Bajraktari-Sylejmani, G. Uhl, P. Davis A, Nair S, Pfister SM, Haefeli WE,
- Weiss J, Burhenne J, Pajtler, KW. Sauter M. Investigating the Central Nervous System
- 1133 Disposition of Actinomycin D: Implementation and Evaluation of Cerebral Microdialysis and
- 1134 Brain Tissue Measurements Supported by UPLC-MS/MS Quantification. Pharmaceutics
- 1135 2021; 13:1498. https://doi.org/10.3390/pharmaceutics13091498.
- 1136 56. Vater J, Crnovčić I, Semsary S, Keller U. MALDI-TOF mass spectrometry, an efficient
- technique for in situ detection and characterization of actinomycins. J Mass Spectrom. 2014
- 1138 ;49(3):210-22. doi: 10.1002/jms.3329. PMID: 24619547.
- 1139 57. Crnovčić I, Vater, J. Keller, U. Occurrence and biosynthesis of C-demethylactinomycins
- in actinomycin-producing Streptomyces chrysomallus and Streptomyces parvulus. J Antibiot,
- 1141 2013;66:211–218. https://doi.org/10.1038/ja.2012.120.
- 114258. Singh, M. P. et al. Mannopeptimycins, new cyclic glycopeptide antibiotics produced by
- 1143 Streptomyces hygroscopicusLL-AC98: Antibacterial and mechanistic activities. Antimicrob.
- 1144 Agents Chemother.2003;47:62-69.
- 114559. Maskey. R. P. et al. Chandranainmycins A-C: Production of novel anticancer antibiotics
- from a marine Actinomadura sp. Isolate M)-48 by variation of medium composition and
- growth conditions. *J. Antibiot.* 2003; 57:1-7.
- 114860. Marfey, P. Determination of D-amino acids. II. Use of a bifunctional reagent, 1,5-difluoro-
- 11492,4-dinitrobenzene. Carlsberg Res. Commun. 1984; 49:59. https://doi.org/10.1007/BF02908688. 1150
- 115161. Kochhar S. and Christen P. Amino acid analysis by high-performance liquid
- 1152chromatography after derivatization with 1-fluoro-2, 4-dinitrophenyl-5-L-ala-nine amide. *Anal.*
- 1153Biochem. 1989; 178:17–21.
- 115562. Goodlett DR, Abuaf PA, Savage PA, Kowalski K.A, Mukherjee TK. Tolan JW., et al.
- 1156Peptide chiral purity determination: hydrolysis in deuter-ated acid derivatization with Marfey's
- 1157reagent and analysis using high-performance liquid chromatography-electrospray ionization-
- 1158mass spectrometry. J. Chromatog. 1995; A707:233–244.
- 116063. Ken-ichi H, Kiyonaga F, Tsuyoshi M, Yasuko H, Makoto S, Yoshitomo I, Hisao O, A
- 1161 method using L/CMS for determination of absolute configuration of constituent amino acids in
- 1162peptide --- advanced Marfey's method., Tetrahedron Letters, 1995;36:9,1515-1518.
- 1163

- 116464. Ayon NJ, Sharma AD, Gutheil WG. LC-MS/MS-Based Separation and Quantification of
- 1165Marfey's Reagent Derivatized Proteinogenic Amino Acid DL-Stereoisomers. J Am Soc Mass 1166Spectrom. 2019;30(3):448-458.
- 11605p
- 116865. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. Licence: CC
- 1169 BY-NC-SA 3.0 IGO.
- 117066. Chiarelli, L. R. et al. A multi target approach to drug discovery inhibiting Mycobacterium
- tuberculosis PyrG and PanK. Nature Sci. Rep. 2018:8;3187.
- 117267. Heo, J. et al. High-content screening of raw actinomycete extracts for the identification of
- antituberculosis activities. *SLAS Discovery*. 2017; 22:144-154.
- 117468. Bu Y. Y. et al. Anti-mycobacterial nucleoside antibiotics from a marine-derived
- 1175 Streptomyces sp. TPU1236A. Mar. Drugs. 2014;12: 6102-6112.
- 69. Chen, C. et al. A marine-derived *Streptomyces* sp. MS449 produces high yield of
- actinomycin X2 and actinomycin D with potent anti-tuberculosis activity. Appl. Microbiol.
- 1178 Biotechnol. 2012;**95:**
- 117970. Dalton JP, et al. Effect of common and experimental anti-tuberculosis treatments on
- 1180 Mycobacterium tuberculosis growing as biofilms. Peer J. 2016;4: e2717.
- 118171. Narendran G, Swaminathan, S. TB-HIV co-infection: a catastrophic comradeship. Oral
- 1182 Dis.2016; 22:46–52.
- 118372. Xu LH, et al. Actinomycete Systematics Principles, Methods, and Practice. Science Press:
- 1184 Beijing (2007).
- 118573. Bauer AW, Kirby, WMM. Antibiotic susceptibility testing by a standardized single disc
- 1186 method. *American J. Clin. Pathol.* 1966; 45:493-496.
- 118774. Staneck JL, Roberts GD. Simplified Approach to Identification of Aerobic Actinomycetes
- by Thin-Layer Chromatography. *Appl. Microbiol. 1974*;28:226-231.
- 118975. Kimura MA, simple method for estimating evolutionary rates of base substitutions through
- comparative studies of nucleotide sequences. J. Mol. Evol. 1980:16:111–120.
- 119176. Eccleston GP, et al. The occurrence of bioactive micromonosporae in aquatic habitats of the
- Sunshine Coast in Australia. *Mar. Drugs.2008*;6: 243–261.
- 119377. Radhakrishnan M, et al. Preliminary screening for antibacterial and antimycobacterial
- 1194 activity of actinomycetes from less explored ecosystems. World J. Microbiol.
- 1195 Biotechnol.2010;26:561-566.

- 119678. Harindran J, et al. HA-1-92, A new antifungal antibiotic produced by Streptomyces CDRIL-
- 1197 312: fermentation, isolation, purification and biological activity. World J. Microbiol.
- 1198 Biotechnol.1999;15:425-430.
- 119979. Augustine SK, et al. A non-polyene antifungal antibiotic from Streptomyces albidoflavus PU
- 1200 23. J. Biosciences. 2005:30201-211.
- 120180. Ojha AK, et al. Growth of Mycobacterium tuberculosis biofilms containing free mycolic
- acids and harbouring drug-tolerant bacteria. *Mol. Microbiol.* 2008;69:164–174.
- 120381. Arumugam, G.S., et al. Significant perspectives on various viral infections targeted antiviral
- drugs and vaccines including COVID-19 pandemicity. Mol Biomed 3, 21 (2022).
- 1205 https://doi.org/10.1186/s43556-022-00078-z
- 120682. Mondal R, et al. (2023) In-vivo studies on Transitmycin, a potent Mycobacterium
- 1207 tuberculosis inhibitor. PLoS ONE 18(3): e0282454.
- 1208 https://doi.org/10.1371/journal.pone.0282454.

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

1221

1222

1223

1224

1225

Discovery of a novel antibiotic, Transitmycin, from *Streptomyces* sp unveils highly efficient activities against tuberculosis and human immunodeficiency virus

Vanaja Kumar*^{1,4}, Balagurunathan Ramasamy², Mukesh Doble ^{\$3,5}, Radhakrishnan Manikkam⁴, Luke Elizabeth Hanna¹, Gandarvakottai Senthilkumar Arumugam³.⁷, Kannan Damodharan³, Suresh Ganesan³, Azger Dusthakeer¹, Precilla Lucia¹, Shainaba A Saadhali¹, Shanthi John², Poongothai Eswaran², Selvakumar Nagamiah¹, Jaleel UCA⁶, Rakhila M⁶, Ayisha Safeeda⁶ and Sathish S⁶

¹National Institute for Research in Tuberculosis, Chennai – 600031, Tamilnadu, India

²Department of Microbiology, Periyar University, Salem – 636011, Tamilnadu, India

³Department of Biotechnology, Indian Institute of Technology, Madras – 600036, Tamilnadu, India

⁴Centre for Drug Discovery and Development, Sathyabama Institute of Science and Technology

(Deemed to be University), Chennai – 600119, Tamilnadu. India

⁵ Saveetha Dental College and Hospitals, 62, Poonamallee High Rd, Chennai, 600077, India

⁶ Open Source Pharma Foundation-National Institute of Advanced Studies Drug Discovery Lab, NIAS, IISc Campus, Bangalore, Karnataka, India
⁷SSS International Drug Discovery & Development Research Private Limited, Innovation & Entrepreneurship, Sudha & Shankar innovation hub, IIT Madras,-600036
Chennai, India

Email: *vanaja kumar51@yahoo.co.in; \$ mukeshdoble.sdc@saveetha.com

Corresponding Author:

Dr. Vanaja Kumar

Former Scientist G & Head

Department of Bacteriology

¹National Institute for Research in Tuberculosis,

Chennai – 600 031. Tamil Nadu. India

Email: vanaja_kumar51@yahoo.co.in

Supplementary Information

	Title	Page Number
S-Table 1.	Phenotypic characteristics of Streptomyces sp. R2	S10
S-Table 2.	Effect of solvents on the extraction of Transitmycin	S11
Figure S1	Characteristic microbial strain and its morphological arrangement	S12
Figure S1a	(a) TLC of Ethyl acetate extract of Streptomyces sp R2 in UV light (b) Long UV (c) Short UV	S13
Figure S2.	Purification of EA extract of Streptomyces sp. R2 by Preparative Thin-Layer Chromatography	S14
Figure S3.	Scheme of purification of EA extract of Streptomyces sp. R2 by Column Chromatograph	S15
Figure S4.	RP HPLC of the ethyl acetate extract of Streptomyces sp. R2 (Batch II)	S16
Figure S5.	Purity of Transitmycin R1, R2, R3 were checked by RP HPLC method	S17
S-Table 3.	HPLC Retention time of R1, R2, R3	S17
Figure S6.	UV/Vis Spectrum of R2 in methanol	S18
Figure S7.	UV/Vis Spectrum of R3 in methanol	S19
Figure S8.	Circular Dichroism Spectrum of Transitmycin (R1) in methanol	S20
Figure S9.	Circular Dichroism Spectrum of R2 in methanol	S21
Figure S10.	Circular Dichroism Spectrum of R3 in methanol	S22
Figure S11.	FT-IR Spectrum of Transitmycin (R1), R2, R3	S23
Figure S12.	FT-IR Spectrum of R2	S24
Figure S13.	FT-IR Spectrum of R3	S25
Table S4.	IR Absorption Frequencies of Functional Groups Present in R1, R2, R3	S26
Figure S14.	¹ H-NMR (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S27
Figure S15.	Expansion of ¹ H-NMR (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S28
Figure S16.	Expansion of ¹ H-NMR (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S29
Figure S17.	Expansion of ¹ H-NMR (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S30
Figure S18.	Expansion of ¹ H-NMR (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S31

	13G NR (105 NR) (105 NR) (105 NR) (105 NR)	S32
Figure S19.	¹³ C-NMR (125 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	
Figure S20.	¹³ C-NMR (125 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S33
Figure S21.	¹³ C-NMR (125 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S34
Figure S22.	¹³ C-NMR (125 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S35
Figure S23	¹³ C-NMR (125 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S36
Figure S24.	¹³ C-NMR (125 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S37
Figure S25.	¹³ C-NMR (125 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S38
Figure S26.	DEPT135 (125 MHz CDCl ₃) Spectrum of Transitmycin (R1)	S39
Figure S27.	COSY (500 MHz) Spectrum of Transitmycin (R1)	S40
Figure S28.	DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)	S41
Figure S29.	Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)	S42
Figure S30.	Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1	S43
Figure S31.	Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)	S44
Figure S32.	Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)	S45
Figure S33.	HMBC (500 MHz) Spectrum of Transitmycin (R1)	S46
Figure S34.	Expansion of HMBC (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S47
Figure S35.	Expansion of HMBC (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S48
Figure S36.	Expansion of HMBC (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1	S49
Figure S37.	Expansion of HMBC (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S50
Figure S38.	Expansion of HMBC (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S51
Figure S39.	Expansion of HMBC (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S52
Figure S40.	Expansion of HMBC (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S53
Figure S41.	HSQC (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S54
Figure S42.	TOCSY (500 MHz) Spectrum of Transitmycin (R1)	S55
Figure S43.	Expansion of TOCSY (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S56

Figure S44.	Expansion of TOCSY (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S57
Figure S45.	Expansion of TOCSY (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S58
Figure S46.	NOESY (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S59
Figure S47.	Expansion of NOESY (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S60
Figure S48.	Expansion of NOESY (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S61
Figure S49.	Expansion of NOESY (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S62
Figure S50.	Expansion of NOESY (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S63
Figure S51.	Expansion of NOESY (500 MHz, CDCl ₃) Spectrum of Transitmycin (R1)	S64
Figure S52.	ROESY (500 MHz) Spectrum of Transitmycin (R1)	S65
Table S5.	NMR data of Transitmycin (R1) in CDCl ₃ (¹ H: 500 MHz ¹³ C: 125 MHz)	S66-72
Figure S53.	¹ H-NMR (500 MHz, CDCl ₃) Spectrum of Compound R2	S73
Figure S54.	¹³ C NMR (125 MHz, CDCl ₃) Spectrum of Compound R 2	S74
Figure S55.	DEPT135&90 (125 MHz CDCl ₃) Spectrum of Compound R2	S75
Figure S56.	Expansion of DEPT135 & 90 (125 MHz, CDCl ₃) Spectrum of Compound R2	S76
Figure S57.	Expansion of DEPT135 & 90 (125 MHz, CDCl ₃) Spectrum of Compound R2	S77
Figure S58.	COSY (500 MHz) Spectrum of Compound R2	S78
Figure S59.	DQF-COSY (500 MHz) Spectrum of Compound R2	S79
Figure S60.	HMBC (500 MHz) Spectrum Compound of R2	S80
Figure S61.	HSQC (500 MHz) Spectrum of Compound R2	S81
Figure S62.	TOCSY (500 MHz) Spectrum of Compound R2	S82
Figure S63.	NOESY (500 MHz) Spectrum of Compound R2	S83
Figure S64.	¹ H-NMR (500 MHz, CDCl ₃) Spectrum of Compound R3	S84
Figure S65.	DQF-COSY (500 MHz) Spectrum of Compound R ₃	S85
Figure S66.	HMBC (500 MHz) Spectrum of Compound R3	S86
Figure S67.	HSQC (500 MHz) Spectrum of Compound R3	S87

E' C(0	TOCGY (500 MII-) Construct of Comment 1D2	S88
Figure S68.	TOCSY (500 MHz) Spectrum of Compound R3	
Figure S69.	NOESY (500 MHz) Spectrum of Compound R3	S89
Figure S70.	MALDI-TOF MS Spectrum of Transitmycin (R1) (Molecular ion peak) (positive mode)	S90
Figure S71.	Expansion of MALDI-TOF MS Spectrum of Transitmycin (R1) (Molecular ion peak)	S91
Figure S72.	Expansion of MALDI-TOF MS Spectrum of Transitmycin (R1) (Molecular ion peak	S92
Figure S73.	MALDI-TOF MS Spectrum of R2 (Molecular ion peak) (positive mode)	S93
Figure S74.	Expansion of MALDI-TOF MS Spectrum of R2 (Molecular ion peak) (positive mode)	S94
Figure S75.	Expansion of MALDI-TOF MS Spectrum of R2 (Molecular ion peak) (Negative mode)	S95
Figure S76.	MALDI-TOF MS Spectrum of R3 (Molecular ion peak) (positive mode)	S96
Figure S77.	MALDI-TOF MS Spectrum of R3 (Molecular ion peak) (Negative mode)	S97
Figure S78.	MALDI-TOF MS Spectrum of Transitmycin (R1) (Positive mode)	S98
Figure S79.	MALDI-TOF MS Spectrum of Transitmycin A (Negative mode)	S99
Table S6.	MALDI-TOF MS Spectral Fragmentation of Transitmycin (R1) (Positive mode)	S100
Figure S80.	MALDI-TOF MS Spectrum of R2 (Positive mode	S101
Figure S81.	MALDI-TOF MS Spectrum of R2 (Negative mode)	S102
Figure S82.	MALDI-TOF MS Spectrum of R3 (Positive mode)	S103
Figure S83.	MALDI-TOF MS Spectrum of R3 (Negative mode)	S104
Figure S84.	QTRAP MS/MS Transitmycin (R1) (Molecular ion peak) (Positive mode)	S105
Figure S85.	QTRAP MS/MS Transitmycin (R1) (Molecular ion peak [M+H] ²⁺ (Positive mode)	S106
Figure S86.	QTRAP MS/MS of Transitmycin (R1) (Molecular ion peak) (Negative mode)	S107
Figure S87.	QTRAP MS/MS of R2 (Molecular ion peak) ((Positive mode)	S108
Figure S88.	QTRAP MS/MS of R2 [M+H] ²⁺ ion peak (Positive mode)	S109
Figure S89.	QTRAP MS/MS of R2 (Molecular ion peak (Positive mode)	S100
Figure S90.	QTRAP MS/MS of R3 Molecular ion peak (Positive mode)	S111
Figure S91.	QTRAP MS/MS of R3 (Molecular ion peak (Negative mode)	S112
Figure S92.	HR-ESI-MS Spectrum of Transitmycin (R1) (Positive mode)	S113
Figure S93.	HR-ESI-MS Spectrum of Transitmycin (R1) (Molecular ion Peak) (Positive mode)	S114

Figure S94. HR-ESI-MS Spectrum of R2 (Positive mode) Figure S95. HR-ESI-MS Spectrum of R2 (Molecular ion Peak) (Positive mode) Figure S96. HR-ESI-MS Spectrum of R3 (Molecular ion Peak) (Positive mode) Figure S97. HR-ESI-MS Spectrum of R3 (Molecular ion Peak) (Positive mode) S118 Figure S98. LC-ESI-MS Spectrum of Transitmycin (R1) (Molecular ion peak) (Positive mode) Figure S100. LC-ESI-MS Spectrum of Transitmycin (R1) (Positive mode). Figure S101. LC-ESI-MS Spectrum of Transitmycin (R1) (Positive mode) Figure S102. LC-ESI-MS Spectrum of Transitmycin (R1) (Positive mode) Figure S103. LC-ESI-MS Spectrum of R2 (Positive mode) Figure S104. LC-ESI-MS Spectrum of R2 (Molecular ion) (Positive mode) Figure S105. LC-ESI-MS Spectrum of R3 (Molecular ion) (Positive mode) Figure S106. LC-ESI-MS Spectrum of R3 (Positive mode) Figure S107. El-MS Spectrum of R3 (Positive mode) Figure S108. El-MS Spectrum of R3 (Positive mode) Figure S109. El-MS Spectrum of (R1) (molecular ion peak) (Positive mode) Figure S109. El-MS Spectrum of (R2) (Positive mode) Figure S109. El-MS Spectrum of (R3) (Positive mode) Figure S109. El-MS Spectrum of (R3) (Positive mode) Figure S109. El-MS Spectrum of (R3) (Positive mode) Figure S110. CHN analysis data of Transitmycin (R1), R2, R3 Figure S111. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode) Figure S112. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S113. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S113. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S115. Sutructural characterisation of Transitmycin (R1) (positive mode) Figure S115. Structural characterisation of Transitmycin (R1) (positive mode) Figure S115. Structural characterisation of Transitmycin (R1) (Positive mode) Figure S115. HPLC analysis of amino acid residue of Transitmycin (R1) (R1) R2, R3 Figure S116. Hydrolysis of amino acid residue of Transitmycin (R1) (R1) R2, R3 Figure S116. Hydrolysis of amino acid			
Figure S96.HR-ESI-MS Spectrum of R3 (Positive mode)\$117Figure S97.HR-ESI-MS Spectrum of R3 (Molecular ion Peak) (Positive mode)\$118Figure S98.LC-ESI-MS Spectrum of Transitmycin (R1) (Molecular ion peak) (Positive mode)\$119Figure S99.LC-ESI-MS Spectrum of Transitmycin (R1) (Positive mode).\$120Figure S101.LC-ESI-MS Spectrum of Transitmycin (R1) (Positive mode)\$121Figure S102.LC-ESI-MS Spectrum of Transitmycin (R1) (Positive mode)\$122Figure S103.LC-ESI-MS Spectrum of R2 (Positive mode)\$123Figure S104.LC-ESI-MS Spectrum of R3 (Positive mode)\$124Figure S105.LC-ESI-MS Spectrum of R3 (Positive mode)\$125Figure S106.EI-MS Spectrum of R3 (Positive mode)\$126Figure S107.EI-MS Spectrum of (R1) (Molecular ion peak) (Positive mode)\$128Figure S108.EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode)\$128Figure S109.EI-MS Spectrum of (R3) (Positive mode)\$130Figure S109.EI-MS Spectrum of (R3) (Positive mode)\$130Figure S110.CHN analysis data of Transitmycin (R1), R2, R3\$131Figure S111.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)\$133Figure S112.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$134Figure S113.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$134Figure S115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$135Figure S115.3200 QTRAP LC/MS/MS Spectr	Figure S94.	HR-ESI-MS Spectrum of R2 (Positive mode)	S115
Figure S97.HR-ESI-MS Spectrum of R3 (Molecular ion Peak) (Positive mode)\$118Figure S98.LC-ESI-MS Spectrum of Transitmycin (R1) (Molecular ion peak) (Positive mode)\$119Figure S99.LC-ESI-MS Spectrum of Transitmycin (R1) (Positive mode)\$120Figure S100.LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)\$121Figure S101.LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)\$122Figure S102.LC-ESI-MS Spectrum of R2 (Positive mode)\$123Figure S103.LC-ESI-MS Spectrum of R2 (Molecular ion) (Positive mode)\$124Figure S104.LC-ESI-MS Spectrum of R3 (Positive mode)\$125Figure S105.LC-ESI-MS Spectrum of R3 (Positive mode)\$126Figure S106.EI-MS Spectrum of R3 (Positive mode)\$127Figure S107.EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode)\$128Figure S109.EI-MS Spectrum of (R2) (Positive mode)\$129Figure S109.EI-MS Spectrum of (R3) (Positive mode)\$130Figure S110.CHN analysis data of Transitmycin (R1), R2, R3\$131Figure S111.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$132Figure S112.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$133Figure S113.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$134Figure S115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$135Figure S115.350 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure S115.350 QTR	Figure S95.	HR-ESI-MS Spectrum of R2 (Molecular ion Peak) (Positive mode)	S116
Figure S98.LC-ESI-MS Spectrum of Transitmycin (R1) (Molecular ion peak) (Positive mode)S119Figure S99.LC-ESI-MS Spectrum of Transitmycin (R1) (Positive mode)S120Figure S100.LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)S121Figure S101.LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)S122Figure S102.LC-ESI-MS Spectrum of R2 (Positive mode)S123Figure S103.LC-ESI-MS Spectrum of R2 (Molecular ion) (Positive mode)S124Figure S104.LC-ESI-MS Spectrum of R3 (Positive mode)S125Figure S105.LC-ESI-MS Spectrum of R3 (Positive mode)S126Figure S106.EI-MS Spectrum of R3 (Positive mode)S127Figure S107.EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode)S128Figure S108.EI-MS Spectrum of (R2) (Positive mode)S129Figure S109.EI-MS Spectrum of (R3) (Positive mode)S130Figure S110.CHN analysis data of Transitmycin (R1), R2, R3S131Figure S111.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)S132Figure S112.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S133Figure S113.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S134Figure S114.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S135Figure S115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S135Figure S115.350 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S136Figure S115.35	Figure S96.	HR-ESI-MS Spectrum of R3 (Positive mode)	S117
Figure S99.LC-ESI-MS Spectrum of Transitmycin (R1) (Positive mode).\$120Figure S100.LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)\$121Figure S101.LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)\$122Figure S102.LC-ESI-MS Spectrum of R2 (Positive mode)\$123Figure S103.LC-ESI-MS Spectrum of R2 (Molecular ion) (Positive mode)\$124Figure S104.LC-ESI-MS Spectrum of R3 (Positive mode).\$125Figure S105.LC-ESI-MS Spectrum of R3 (Positive mode)\$126Figure S106.EI-MS Spectrum of R3 (Positive mode)\$127Figure S107.EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode)\$128Figure S108.EI-MS Spectrum of (R2) (Positive mode)\$128Figure S109.EI-MS Spectrum of (R2) (Positive mode)\$130Figure S110.CHN analysis data of Transitmycin (R1), R2, R3\$131Figure S111.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)\$132Figure S112.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$133Figure S113.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$134Figure S114.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$135Figure S115.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure S115.\$500 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure S115.\$500 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure S115.\$500 QTRA	Figure S97.	HR-ESI-MS Spectrum of R3 (Molecular ion Peak) (Positive mode)	S118
Figure S100.LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)S121Figure S101.LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)S122Figure S102.LC-ESI-MS Spectrum of R2 (Positive mode)S123Figure S103.LC-ESI-MS Spectrum of R2 (Molecular ion) (Positive mode)S124Figure S104.LC-ESI-MS Spectrum of R3 (Positive mode).S125Figure S105.LC-ESI-MS Spectrum of R3 (Positive mode)S126Figure S106.EI-MS Spectrum of Transitmycin (R1) (Positive mode)S127Figure S107.EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode)S128Figure S109.EI-MS Spectrum of (R2) (Positive mode)S129Figure S109.EI-MS Spectrum of (R3) (Positive mode)S130Figure S110.CHN analysis data of Transitmycin (R1), R2, R3S131Figure S111.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)S132Figure S112.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S133Figure S113.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S133Figure S114.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S135Figure S115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S136Figure S115.3500 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S136Figure S15.Structural characterisation of Transitmycin (R1) (M+H]+ obtained by QTRAP LC-MS/MSS137Table S7a.Structural characterisation of Transitmycin (R1) [M+H]+ obtained by QTRAP LCMS/MS<	Figure S98.	LC-ESI-MS Spectrum of Transitmycin (R1) (Molecular ion peak) (Positive mode)	S119
Figure \$101.LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)\$122Figure \$102.LC-ESI-MS Spectrum of R2 (Positive mode)\$123Figure \$103.LC-ESI-MS Spectrum of R2 (Molecular ion) (Positive mode)\$124Figure \$104.LC-ESI-MS Spectrum of R3 (Positive mode).\$125Figure \$105.LC-ESI-MS Spectrum of R3 (Positive mode)\$126Figure \$106.EI-MS Spectrum of Transitmycin (R1) (Positive mode)\$127Figure \$107.EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode)\$128Figure \$108.EI-MS Spectrum of (R2) (Positive mode)\$129Figure \$109.EI-MS Spectrum of (R3) (Positive mode)\$130Figure \$110.CHN analysis data of Transitmycin (R1), R2, R3\$131Figure \$111.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)\$132Figure \$112.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$133Figure \$113.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$134Figure \$114.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$135Figure \$115.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure \$115.\$500 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure \$115.\$500 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure \$15.\$500 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure \$15.\$500 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) [M+H]+ obtained by QTRAP LCMS/MS\$	Figure S99.	LC-ESI-MS Spectrum of Transitmycin (R1) (Positive mode).	S120
Figure \$102.LC-ESI-MS Spectrum of R2 (Positive mode)\$123Figure \$103.LC-ESI-MS Spectrum of R2 (Molecular ion) (Positive mode)\$124Figure \$104.LC-ESI-MS Spectrum of R3 (Positive mode).\$125Figure \$105.LC-ESI-MS Spectrum of R3 (Positive mode)\$126Figure \$106.EI-MS Spectrum of Transitmycin (R1) (Positive mode)\$127Figure \$107.EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode)\$128Figure \$108.EI-MS Spectrum of (R2) (Positive mode)\$129Figure \$109.EI-MS Spectrum of (R3) (Positive mode)\$130Figure \$110.CHN analysis data of Transitmycin (R1), R2, R3\$131Figure \$111.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)\$132Figure \$112.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$133Figure \$113.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$134Figure \$114.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$135Figure \$115.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure \$115.\$200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure \$115.\$500 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure \$15.\$500 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure \$15.\$500 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure \$15.\$500 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (M+H)+ obtained by QTRAP LCMS/MS	Figure S100.	LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)	S121
Figure \$103.LC-ESI-MS Spectrum of R2 (Molecular ion) (Positive mode)\$124Figure \$104.LC-ESI-MS Spectrum of R3 (Positive mode).\$125Figure \$105.LC-ESI-MS Spectrum of R3 (Positive mode)\$126Figure \$106.EI-MS Spectrum of Transitmycin (R1) (Positive mode)\$127Figure \$107.EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode)\$128Figure \$108.EI-MS Spectrum of (R2) (Positive mode)\$129Figure \$109.EI-MS Spectrum of (R3) (Positive mode)\$130Figure \$110.CHN analysis data of Transitmycin (R1), R2, R3\$131Figure \$111.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)\$132Figure \$112.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$133Figure \$113.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$134Figure \$114.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$135Figure \$115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure \$115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure \$115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure \$15.3500 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure \$15.3500 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)\$136Figure \$15.3500 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) [M+H]+ obtained by QTRAP LCMS/MS\$137Table \$7a.Structural characterisation of Transitmyci	Figure S101.	LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)	S122
Figure S104. LC-ESI-MS Spectrum of R3 (Positive mode). Figure S105. LC-ESI-MS Spectrum of R3 (Positive mode) Figure S106. EI-MS Spectrum of Transitmycin (R1) (Positive mode) Figure S107. EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode) Figure S108. EI-MS Spectrum of (R2) (Positive mode) Figure S109. EI-MS Spectrum of (R3) (Positive mode) Figure S110. CHN analysis data of Transitmycin (R1), R2, R3 Figure S111. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode) Figure S112. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S113. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S114. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S115. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) S136 Figure S115. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) S136 Figure S115 a, b Structural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MS S137 Table S7a. Structural characterisation of Transitmycin (R1) [M+H] ⁺ obtained by QTRAP LCMS/MS S139 Figure S116. Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3	Figure S102.	LC-ESI-MS Spectrum of R2 (Positive mode)	S123
Figure S105.LC-ESI-MS Spectrum of R3 (Positive mode)S126Figure S106.EI-MS Spectrum of Transitmycin (R1) (Positive mode)S127Figure S107.EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode)S128Figure S108.EI-MS Spectrum of (R2) (Positive mode)S129Figure S109.EI-MS Spectrum of (R3) (Positive mode)S130Figure S110.CHN analysis data of Transitmycin (R1), R2, R3S131Figure S111.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)S132Figure S112.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S133Figure S113.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S134Figure S114.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S135Figure S115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S136Figure S115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S136Figure S115.Structural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MSS137Table S7a.Structural characterisation of Transitmycin (R1) [M+H]+ obtained by QTRAP LCMS/MSS138Table S7b.Structural characterisation of Transitmycin (R1) [M+Na]+ obtained by QTRAP LCMS/MSS139Figure S116.Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3S140	Figure S103.	LC-ESI-MS Spectrum of R2 (Molecular ion) (Positive mode)	S124
Figure S106.EI-MS Spectrum of Transitmycin (R1) (Positive mode)S127Figure S107.EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode)S128Figure S108.EI-MS Spectrum of (R2) (Positive mode)S129Figure S109.EI-MS Spectrum of (R3) (Positive mode)S130Figure S110.CHN analysis data of Transitmycin (R1), R2, R3S131Figure S111.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)S132Figure S112.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S133Figure S113.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S134Figure S114.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S135Figure S115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S136Figure S115 a, bStructural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MSS137Table S7a.Structural characterisation of Transitmycin (R1) [M+H]+ obtained by QTRAP LCMS/MSS138Table S7b.Structural characterisation of Transitmycin (R1) [M+Na]+ obtained by QTRAP LCMS/MSS139Figure S116.Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3S140	Figure S104.	LC-ESI-MS Spectrum of R3 (Positive mode).	S125
Figure S107.EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode)S128Figure S108.EI-MS Spectrum of (R2) (Positive mode)S129Figure S109.EI-MS Spectrum of (R3) (Positive mode)S130Figure S110.CHN analysis data of Transitmycin (R1), R2, R3S131Figure S111.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)S132Figure S112.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S133Figure S113.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S134Figure S114.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S135Figure S115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S136Figure S115 a, bStructural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MSS137Table S7a.Structural characterisation of Transitmycin (R1) [M+H]+ obtained by QTRAP LCMS/MSS138Table S7b.Structural characterisation of Transitmycin (R1) [M+Na]+ obtained by QTRAP LCMS/MSS139Figure S116.Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3S140	Figure S105.	LC-ESI-MS Spectrum of R3 (Positive mode)	S126
Figure S108. EI-MS Spectrum of (R2) (Positive mode) Figure S109. EI-MS Spectrum of (R3) (Positive mode) Figure S110. CHN analysis data of Transitmycin (R1), R2, R3 Figure S111. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode) Figure S112. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S113. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S114. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S115. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S115. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S115. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S115. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) S136 Figure S115. Structural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MS S137 Table S7a. Structural characterisation of Transitmycin (R1) [M+H] ⁺ obtained by QTRAP LCMS/MS S138 Table S7b. Structural characterisation of Transitmycin (R1) [M+Na] ⁺ obtained by QTRAP LCMS/MS S139 Figure S116. Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3	Figure S106.	EI-MS Spectrum of Transitmycin (R1) (Positive mode)	S127
Figure S109. EI-MS Spectrum of (R3) (Positive mode) Figure S110. CHN analysis data of Transitmycin (R1), R2, R3 Figure S111. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode) Figure S112. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S113. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S114. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S115. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S115. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode) Figure S115 a, b Structural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MS Table S7a. Structural characterisation of Transitmycin (R1) [M+H] ⁺ obtained by QTRAP LCMS/MS S138 Table S7b. Structural characterisation of Transitmycin (R1) [M+Na] ⁺ obtained by QTRAP LCMS/MS S139 Figure S116. Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3	Figure S107.	EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode)	S128
Figure S110.CHN analysis data of Transitmycin (R1), R2, R3S131Figure S111.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)S132Figure S112.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S133Figure S113.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S134Figure S114.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S135Figure S115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S136Figure S115 a, bStructural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MSS137Table S7a.Structural characterisation of Transitmycin (R1) [M+H]+ obtained by QTRAP LCMS/MSS138Table S7b.Structural characterisation of Transitmycin (R1) [M+Na]+ obtained by QTRAP LCMS/MSS139Figure S116.Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3S140	Figure S108.	EI-MS Spectrum of (R2) (Positive mode)	S129
Figure S111.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)S132Figure S112.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S133Figure S113.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S134Figure S114.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S135Figure S115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S136Figure S115 a, bStructural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MSS137Table S7a.Structural characterisation of Transitmycin (R1) [M+H]+ obtained by QTRAP LCMS/MSS138Table S7b.Structural characterisation of Transitmycin (R1) [M+Na]+ obtained by QTRAP LCMS/MSS139Figure S116.Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3S140	Figure S109.	EI-MS Spectrum of (R3) (Positive mode)	S130
Figure S112.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S133Figure S113.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S134Figure S114.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S135Figure S115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S136Figure S115 a, bStructural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MSS137Table S7a.Structural characterisation of Transitmycin (R1) [M+H]+ obtained by QTRAP LCMS/MSS138Table S7b.Structural characterisation of Transitmycin (R1) [M+Na]+ obtained by QTRAP LCMS/MSS139Figure S116.Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3S140	Figure S110.	CHN analysis data of Transitmycin (R1), R2, R3	S131
Figure S113.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S134Figure S114.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S135Figure S115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S136Figure S115 a, bStructural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MSS137Table S7a.Structural characterisation of Transitmycin (R1) [M+H]+ obtained by QTRAP LCMS/MSS138Table S7b.Structural characterisation of Transitmycin (R1) [M+Na]+ obtained by QTRAP LCMS/MSS139Figure S116.Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3S140	Figure S111.	3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)	S132
Figure S114.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S135Figure S115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S136Figure S115 a, bStructural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MSS137Table S7a.Structural characterisation of Transitmycin (R1) [M+H]+ obtained by QTRAP LCMS/MSS138Table S7b.Structural characterisation of Transitmycin (R1) [M+Na]+ obtained by QTRAP LCMS/MSS139Figure S116.Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3S140	Figure S112.	3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)	S133
Figure S115.3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)S136Figure S115 a, bStructural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MSS137Table S7a.Structural characterisation of Transitmycin (R1) [M+H]+ obtained by QTRAP LCMS/MSS138Table S7b.Structural characterisation of Transitmycin (R1) [M+Na]+ obtained by QTRAP LCMS/MSS139Figure S116.Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3S140	Figure S113.	3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)	S134
Figure S115 a, bStructural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MSS137Table S7a.Structural characterisation of Transitmycin (R1) [M+H]+ obtained by QTRAP LCMS/MSS138Table S7b.Structural characterisation of Transitmycin (R1) [M+Na]+ obtained by QTRAP LCMS/MSS139Figure S116.Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3S140	Figure S114.	3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)	S135
Table S7a.Structural characterisation of Transitmycin (R1) [M+H]+ obtained by QTRAP LCMS/MSS138Table S7b.Structural characterisation of Transitmycin (R1) [M+Na]+ obtained by QTRAP LCMS/MSS139Figure S116.Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3S140	Figure S115.	3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)	S136
Table S7b.Structural characterisation of Transitmycin (R1) [M+Na]+ obtained by QTRAP LCMS/MSS139Figure S116.Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3S140	Figure S115 a, b	Structural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MS	S137
Figure S116. Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3 S140	Table S7a.	Structural characterisation of Transitmycin (R1) [M+H] ⁺ obtained by QTRAP LCMS/MS	S138
	Table S7b.	Structural characterisation of Transitmycin (R1) [M+Na] ⁺ obtained by QTRAP LCMS/MS	S139
Figure S117a. HPLC analysis of standard L-FDAA-D/L-Valine S141a	Figure S116.	Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3	S140
	Figure S117a.	HPLC analysis of standard L-FDAA-D/L-Valine	S141a

T: 011#1	TIDLO 1 1 C 1 1 TD 1 A D V I	C1 / 11-
Figure S117b.	HPLC analysis of standard L-FDAA-D-Valine	S141b
Figure S117c.	HPLC analysis of standard L-FDAA-L-Valine	S141c
Figure S118 a.	HPLC analysis of standard L-FDAA-D/L-Proline	S142a
Figure S118 b.	HPLC analysis of standard L-FDAA-D-Proline	S142b
Figure S118c.	HPLC analysis of standard L-FDAA-L-Proline	S142c
Figure S119a.	HPLC analysis of standard L-FDAA-D/L-Threonine	S143a
Figure S119b.	HPLC analysis of standard L-FDAA-D-Threonine	S143b
Figure S119c.	HPLC analysis of standard L-FDAA-D-Threonine	S143c
Figure S120a.	HPLC analysis of standard L-FDAA-D/L-N-Methyl Valine	S144a
Figure S120b.	HPLC analysis of standard L-FDAA-D-N-Methyl Valine	S144b
Figure S120c.	HPLC analysis of standard L-FDAA-D-N-Methyl Valine	S144c
Figure S121a.	HPLC analysis of standard L-FDAA-D-Valine	S145a
Figure S121b.	HPLC analysis of standard L-FDAA-L-Valine	S145b
Figure S121c.	HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of Transitmycin (R1)	S143a
Figure 122a.	HPLC analysis of standard L-FDAA-D-Valine	S143b
Figure S122b.	HPLC analysis of standard L-FDAA-L-Valine	S143c
Figure S122c.	HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of R2	S144a
Figure S123a.	HPLC analysis of standard L-FDAA-D-Valine	S144b
Figure S123b.	HPLC analysis of standard L-FDAA-L-Valine	S144c
Figure S123c.	HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of R3	S145
Figure S124.	HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of R2	S148
Figure S125.	HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of R3	S149
Table 8a.	Analysis of L-FDAA derivates of acid hydrolysate of R2 by HPLC	S150
Table 8b.	Analysis of L-FDAA derivatives of acid hydrolysate of R3 by HPLC	S150
Figure S126.	ESI- MS Spectrum of Marfey's Derivatives of Transitmycin (R1) (Positive mode)	S151
Figure S127.	ESI- MS Spectrum of Marfey's Derivatives of Transitmycin (R1) (Positive mode)	S152
Figure S128.	LCMS analysis of Standard L-FDAA-D-Proline (Positive mode)	S153

Figure S129.	LCMS analysis of Standard L-FDAA-D-Proline (Negative mode)	S154
Figure S130.	LCMS analysis of Standard L-FDAA-L-Proline (Positive mode	S155
Figure S131.	LCMS analysis of Standard L-FDAA-L-Proline (Negative mode)	S156
Figure S132.	LCMS analysis of Standard L-FDAA-D/L-Proline (Positive mode)	S157
Figure S133.	LCMS analysis of Standard L-FDAA-D/L-Proline (Negative mode)	S158
Figure S134.	LCMS analysis of Standard L-FDAA-D-Valine (Positive mode)	S159
Figure S135.	LCMS analysis of Standard L-FDAA-D-Valine (Negative mode)	S160
Figure S136.	LCMS analysis of Standard L-FDAA-L-Valine (Positive mode)	S161
Figure S137.	LCMS analysis of Standard L-FDAA-L-Valine (Negative mode)	S162
Figure S138.	LCMS analysis of Standard L-FDAA-D/L-Valine (Positive mode)	S163
Figure S139.	LCMS analysis of Standard L-FDAA-D/L-Valine (Negative mode)	S164
Figure S140.	LCMS analysis of Standard L-FDAA-D/L-Valine (Positive mode)	S165
Figure S141.	LCMS analysis of Standard L-FDAA-D/L-Valine (Negative mode)	S166
Figure S142.	LCMS analysis of Standard L-FDAA-D-Threonine (Positive mode)	S167
Figure S143.	LCMS analysis of Standard L-FDAA-D-Threonine (Negative mode)	S168
Figure S144.	LCMS analysis of Standard L-FDAA-D/L Threonine (Positive mode)	S169
Figure S 145.	LCMS analysis of Standard L-FDAA-D/L Threonine (Negative mode)	S170
Figure S146.	LCMS analysis of Standard L-FDAA-D/L N-Methyl valine (Positive mode).	S171
Figure S147.	LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Positive mode)	S172
Figure S148.	LCMS analysis of Standard L-FDAA-L N-Methyl valine (Positive mode)	S173
Figure S149.	LCMS analysis of Standard L-FDAA-L- N-Methyl valine (Positive mode)	S174
Figure S150.	LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Positive mode)	S175
Figure S151.	LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Positive mode)	S176
Figure S152.	LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Negative mode)	S177
Figure S153.	LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Positive mode)	S178
Figure S154.	LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Positive mode)	S179
Figure S155.	LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Positive mode)	S180

Figure S156.	LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Negative mode).	S181
Figure S157.	LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Negative mode)	S182
Figure S158.	LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Negative mode).	S183
Figure S159.	LCMS analysis of L-FDAA derivatives of Transitmycin (R1) (Positive mode)	S184
Figure S160.	LCMS analysis of L-FDAA derivatives of Transitmycin (R1) (Negative mode)	S185
Figure S161.	LCMS analysis of L-FDAA derivatives of R3 (Positive mode)	S186
Table S9a.	Analysis of L-FDAA derivates of acid hydrolysate of Transitmycin R1 by HPLC-MS	S187
Table S9b.	Analysis of L-FDAA derivates of acid hydrolysate of R3 by HPLCMS	S187
Table S10.	Physico-chemical properties of R2	S188-89
Table S11.	Physico-chemical properties of R3	S190-91
Table S12	Drug resistant profile of the clinical isolates of <i>Mycobacterium tuberculosis</i> used to determine the anti TB activity of Transitmycin	S192-194
Table S13	Anti-HIV activity of Transitmycin on various HIV-1 subtypes	S195

S-Table 1. Phenotypic characteristics of *Streptomyces* sp. R2

Characteristics	Results
Micromorphology	
Aerial mycelium	Present
Substrate mycelium	Present
Spore chain morphology	Rectus flexibile, non fragmented
Spore surface	Hairy
Cultural characteristics	
Colony consistency	Powdery
Aerial mass colour	Ash white
Reverse side pigment	Yellow
Soluble pigment	Yellow
Melanoid pigment	Absent
Growth on Different media	
ISP1	Moderate
ISP2	Good
ISP3	Good
ISP4	Good
ISP5	Moderate
ISP6	Moderate
ISP7	Good
Carbon utilization	
Glucose	Good
Arabinose	Poor
Sucrose	Poor
Xylose	Moderate
Inositol	Poor
Mannitol	Good

Fructose Moderate
Rhamnose Moderate
Raffinose No Growth
Cellulose No Growth

pH tolerance

No growth
Good
Good
Moderate

Growth at

 20^{0} C Poor 30^{0} C Good 40^{0} C Good 50^{0} C Moderate

NaCl tolerance (%)

0 Poor
1 Good
2.5 Good
5 Good
7.5 Poor

No growth

Susceptibility to Tetracycline, chloramphenicol, erythromycin, gentamicin, vancomycin

Resistant to Penicillin, nystatin, nalidixic acid

S-Table 2. Effect of solvents on the extraction of Transitmycin

Solvents	Quantity of extracts	Antibacterial activity against S. aureus MTCC 96	Anti TB activity (% reduction in RLU)
Methanol	40	14	58.31
Chloroform	41	9	18.07
Dichloromethane	40	13	22.71
Diethyl ether	10	14	74.23
Ethyl acetate	9	19	83.40
n-hexane	-	-	-





Fig. S1. Characteristic microbial strain and its morphological arrangement. **a** Cultural morphology and microscopic visualization. **b** SEM image (3,500X) of Streptomyces variabilis R2 on ISP2 agar medium. **c** Phylogenetic dendrogram obtained by distance matrix analysis of 16s rRNA gene sequences, showing the position of strain R2 among its phylogenetic neighbours.




Solvent system for TLC: Ethyl acetate /Methanol, (9.5:0.5)


Rf value of Transitmycin (R1) = 0.8

Rf value of R2 = 0.6

Rf value of R3 = 0.3

Solvent system for TLC: Ethyl acetate/Methanol, (9.5:0.5) (a) TLC of Ethyl acetate extract of Streptomyces sp. R2 in UV light (b) Long UV (c) Short UV





Solvent used for Preparative TLC: Ethylacetate:methanol, (9.5:0.5)

Figure S2. Purification of EA extract of Streptomyces sp. R2 by Preparative Thin-Layer Chromatography

Extraction and Isolation

Purification of compounds were performed by preparative thin layer chromatography (TLC) using Merck silica gel 60 (GF254) pre coated aluminium (6x8 cm size) plates. The crude pigment was purified by using preparative thin layer chromatography commercially available pre coated silica gel chromatography sheets (6×8 cm size) were used. To find out the best solvent system to separate the crude compound, the solvents were used in different proportions, among all solvent systems used, Ethylacetate: methanol (9.5:0.5) showed good separation. The crude pigment (2 g) was dissolved in 5 mL of ethyl acetate. With the help of capillary tube, the sample was spotted at the bottom of silica gel coated sheet (6 x 8 cm) and then it was placed in the developing 100 mL beaker containing mobile phase (Ethyl acetate/Methanol, 9.5:0.5) 5 mL, covered with the watch glass in order to prevent the evaporation of the solvents. The solvent was allowed to run till it reaches about half a centimetre below the top of the plate. After running, the 200 sheets were kept at room temperature for the complete drying of the plate. Spots on TLC were detected under UV light (254 and 365 nm) and by spraying with concentrated H₂SO₄ followed by heating at 105 °C for 5 min. After drying, the yellow pigment spot was scrapped, mixed with ethyl acetate and filtered using funnel fitted with what man filtered paper and Ethyl acetate was evaporated to dryness under vacuum to afford the pure compound Transitmucin R1 (10 mg), R 2 (10 mg), R3 (5 mg). Rf value of the spot separated on the TLC plate was determined. The solvent system Ethyl acetate: methanol (9.5:0.5) was found to have good separation with single spot when compared to all the solvent systems used for TLC.



Column chromatography was carried out on Neutral Alumina (230-400 mesh) and Column size: (id 30m × 90 cm). The crude ethyl acetate extract Streptomyces sp (R2) was purified using column chromatography packed with neutral alumina using a gradient of 1% Methanol/Chloroform mixture (CH3OH/ CHCl3) was used as the eluent. Fractions were collected and concentrated under vacuum to afford pure compounds. The desired product was monitored in a TLC with pre coated alumina sheet silica. The isolated compounds were obtained Transitmycin (R1) (200 mg), R2 (100 mg), R3 (50 mg).

Figure S3 (a) Crude (b) Crude with alumina (c) Before elution (d) After elution (e) solution form (f) solid form (g) After drying (h) TLC (i) R**P-HPLC**




Figure S3. Scheme of purification of EA extract of *Streptomyces* sp. R2 by column chromatography







Figure S4. RP HPLC of the crude ethyl acetate extract of *Streptomyces* **sp. R2** (Batch II)Analytical HPLC condition: Luna 5u C₁₈ (2) 100 (150 X 4.6 mm) Solvent system: A: B (35: 65 v/v); flow rate 2 ml/min, 254 nm Solvent A: Acetonitrile; Solvent B: Water, Detection: PDA, Injection volume: 20µl, Column Temperature: 30 °C





a	Ret. Time of R1	5.807 min
b	Ret. Time of R1	3.062 min
С	Ret. Time of R2	1.100 min






Figure S5. Purity of Transitmycin R1, R2, R3 were checked by RP HPLC method




Figure S6: UV/Vis Spectrum of R2 in methanol [UV: (MeOH) λ max, (log ϵ) 205, (1.25), 240 (0.63), 425 (0.39), 442(0.42) nm]




Figure S7. UV/Vis Spectrum of R3 in methanol [UV (MeOH) λ max (log ϵ) 206 (1.90), 240 (0.69) 424 (0.191), 442.2 (0.19) nm]




Figure S8. Circular Dichroism Spectrum of Transitmycin (R1) in methanol CD: [MeOH, [nm], (mdeg)]: $\lambda_{max}(\Delta\epsilon)$ 195 (+11.1), 210 (-21.0), 242 (+4.7)




Figure S9. Circular Dichroism Spectrum of R2 in methanol CD: [MeOH, [nm], (mdeg)]: λ_{max} , ($\Delta\epsilon$) 195 (+8.8), 210 (-22.0), 240 (+4.3) nm




Figure S10. Circular Dichroism Spectrum of R3 in methanol CD: [MeOH, [nm], (mdeg)] $\lambda_{max}(\Delta\epsilon)$ 195 (+24.0), 210 (-21.5), 241 (+1.7)




Figure S11. FT-IR Spectrum of Transitmycin (R1), R2, R3




Figure S12. FT-IR Spectrum of R2




Figure S13. FT-IR Spectrum of R3

R1	IR (KBr cm ⁻¹), 3435 cm ⁻¹ for NH, 2958, 2924 cm ⁻¹ (m, -CH str, asym, CH ₃ and CH ₂), 2872 cm ⁻¹ , 2853 cm ⁻¹ (m, -CH str, sym, CH ₃ and CH ₂), 1746 cm ⁻¹ (s, C=O str, lactone ring), 1642 cm ⁻¹ (s, -C=O str, 2 ⁰ amide), 1524, 1503 (m, -NH bend, 2 ⁰ amide), 1466 (m, CH bend (scissoring), CH ₂), 1379 cm ⁻¹ (s, -CH bend, isopropyl group), 1268 (s, C-O str, ester), 1194 (C-O-C of lactone) 1099, 1059, 1017 (s, C-O or C-N), 720, 712, 694,
R2	689 (s, -CH bend, oop, aromatic ring), 909 (w, CH ₃ rocking). IR (KBr cm ⁻¹), 3436 cm ⁻¹ for NH, 2961, 2924 cm ⁻¹ (m, -CH str, asym, CH ₃ and CH ₂), 2872 cm ⁻¹ , 2853 cm ⁻¹ (m, -CH str, sym, CH ₃ and CH ₂),1744 cm ⁻¹ (s, C=O str, lactone ring), 1650 cm ⁻¹ (s, -C=O str, 2 ⁰ amide),1565, 1503 (m, -NH bend, 2 ⁰ amide), 1415 (m, CH bend (scissoring), CH ₂), 1318 cm ⁻¹ (s, -CH bend, isopropyl group), 1268, 1204 (s, C-O str, ester),1140 (C-O-C of lactone), 1045, 1019 (s, C-O or C-N), 720, 712, 653 (s, -CH bend, oop, aromatic ring), 929 (w, CH ₃ rocking).
R3	IR (KBr cm ⁻¹), 3415 cm ⁻¹ for NH, 2957, 2924 cm ⁻¹ (m, -CH str, asym, CH ₃ and CH ₂), 2872 cm ⁻¹ , 2853 cm ⁻¹ (m, -CH str, sym, CH ₃ and CH ₂),1745 cm ⁻¹ (s, C=O str, lactone ring), 1642 cm ⁻¹ (s, -C=O str, 2 ⁰ amide), 1583, 1507 (m, -NH bend, 2 ⁰ amide), 1464 (m, CH bend (scissoring), CH ₂), 1384, 1301 cm ⁻¹ (s, -CH bend, isopropyl group), 1266, 1228 (s, C-O str, ester),1193 (C-O-C of lactone) ,1093, 1078, 1017 (s, C-O or C-N), 909 (w, CH ₃ rocking) 720, 712, 694, 689 (s, -CH bend, oop, aromatic ring).

Table S4. IR Absorption Frequencies of Functional Groups Present in Transitmycin (R1), R2, R3




Figure S14. ¹H-NMR (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S15. Expansion of ¹H-NMR (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S16. Expansion of ¹H-NMR (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S17. Expansion of ¹H-NMR (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S18. Expansion of $^1\text{H-NMR}$ (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S19. ¹³C-NMR (125 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S20. ¹³C-NMR (125 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S21. ¹³C-NMR (125 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S22. ¹³C-NMR (125 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S23. ¹³C-NMR (125 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S24. ¹³C-NMR (125 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S25. ¹³C-NMR (125 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S26. DEPT135 (125 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S27. COSY (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S28. DQF-COSY (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S29. Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)




Figure S30. Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)




Figure S31. Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)




Figure S32. Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)




Figure 33. HMBC (500 MHz) Spectrum of Transitmycin (R1)




Figure S34. Expansion of HMBC (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S35. Expansion of HMBC (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S36. Expansion of HMBC (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S37. Expansion of HMBC (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S38. Expansion of HMBC (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S39. Expansion of HMBC (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S40. Expansion of HMBC (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S41. HSQC (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S42. TOCSY (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S43. Expansion of TOCSY (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S44. Expansion of TOCSY (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S45. Expansion of TOCSY (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S46. NOESY (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S47. Expansion of NOESY (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S48. Expansion of NOESY (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S49. Expansion of NOESY (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S50. Expansion of NOESY (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S51. Expansion of NOESY (500 MHz, CDCl₃) Spectrum of Transitmycin (R1)




Figure S52. ROESY (500 MHz) Spectrum of Transitmycin (R1)

Table S5: NMR data of Trasitmycin (R1) in CDCl₃ (¹H: 500 MHz ¹³C: 125 MHz)

α- ring	position	δC	δН	J (Hz)	COSY	TOCSY	НМВС	ROSEY
Thr	1	168.8	-					
	2	54.6	4.60	d, 10.0	3, 4, -NH	3, 4	1, 3, 13	3, 4, 2-Val, Val-NH
	3	74.7	5.13	m	2, 4,- NH	2, 4,	4	2, 4, Val-NH
	4	17.0	1.10	d, 6.5	2, 3	2, 3, -NH	2, 3	2, 3, Val-NH
	NH	-	7.29	d, 7.0	2, 3, 4	2, 3, 4	1, 3, 13	2, 4
L-Val	1	173.4						
	2	58.7	3.58	dd, 10.5,6.5	3, 4, 5, - NH	3, 4, 5, - NH	1, 5, 1-Thr	3, 4, 5, 2-Pro
	3	31.7	2.08	m	2, 4, 5	2, 4, 5	2,5	4, 5, 4-Thr
	4	19.0	0.89	d, 7.0	2, 3	2, 3, -NH	2,3,5	2, 3, 5
	5	18.9	1.13	d, 6.5	2, 3	2, 3, -NH	2,3,4	2, 3, 2-Val, Val-NH
	NH	-	7.74	d, 5.5	2, 3, 4, 5	2, 3, 4, 5	2, 3, 1-Thr	2, 3, 4, 5 2- Thr, 3-Thr
Pro	1	173.1	-					
	2	56.4	5.93	d, 9.5	3a,3b,4a,4b	3a,3b 4a,	3, 4, 5,	3a, 3b,

						4b	1-Val	2a-Sar,2b-Sar, Sar-NMe
	3	31.6	2.73 1.84	dd, 17.5,7.0 dd, 19.5, 6.5	3b, 4a, 4b 3a, 4a,	3b, 4a, 4b 3a, 4a,	1, 2, 4 1, 4, 5	3b, 2a-Sar, 2b-Sar 3a, 4a, 4b
	4	23.3	2.26 2.01	d, 16.5 d, 8.0	3a, 3b, 4b 3b, 4a	3a, 3b, 4b 3b, 4a	3, 5 3, 5	4b, 5a, 5b 4a, 5a
	5a 5b	47.8	3.86 3.67	d, 18.5 d, 18.5	3a, 4a, 4b 3a, 4a, 4b	3a, 4a, 4b 3a, 4a, 4b	4, 1-Val	5b
Sar	1	166.2	-					
	2	51.2	2a, 4.70 2b, 3.64	d, 17.5 d, 17.5	2b 2a	2b, NMe 2a, NMe	1, NMe,1- pro 1, NMe,1- Pro	2b, NMe, 2-Pro 4-MeVal, 5-MeVal, NMe
	N-Me	34.9	2.87	S		2a, 2b	2, 1-Pro	2b, 3-MeVal
MeVal	1	167.4	-					
	2	71.3	2.70	d, 9.0	3, 4, 5	3, 4, 5	1, 3,4,NMe	4, 5
	3	26.9	2.62	d, 7.0	2, 4, 5	2, 4, 5	1, 3, 4, 5, NMe	4, 5

4	21.6	0.96	d, 6.0	2, 3	2, 3, 5	2, 3, 5	3
5	19.2	0.72	d, 6.5	2, 3	2, 3, 4	2, 3, 4	3
N-Me	39.2	2.89	S	-	2, 3	2, 1-Sar	2, 3, 5, 2a-Sar, 2b-Sar

β- ring	position	δC	δН	J (Hz)	COSY	TOCSY	HMBC	NOESY
Thr	1	168.9	-					
	2	54.9	4.50	d, 9.0	3,4, -NH	3, 4	1, 3, 14	3, 4, 2-Val, Val- NH
	3	74.6	5.23	m	2,4,- NH	2, 4	4	2,4, Val-NH
	4	17.6	1.20	d, 6.0	2, 3	2, 3, - NH	2, 3	2,3, Val-NH
	NH	-	7.68	d, 6.0	2, 3, 4	2, 3, 4	1, 3, 14	2, 4
L-Val	1	173.9	-					
	2	57.1	3.71	dd, 10.5, 6.5	3, 4, 5, -NH	3, 4, 5, -NH	1, 3, 5, 1-Thr,	3, 4, 5, 2-Oxo pro
	3	31.8	2.20	m	2, 4, 5	2, 4, 5	2, 5	4, 5, 4-Thr
	4	19.0	0.86	d, 7.0	2, 3	2, 3, -NH	2, 3, 5	2, 3, 5
	5	18.8	1.14	d, 7.0	2, 3	2, 3, -NH	2, 3, 4	2, 3, 2-Val, Val- NH
	NH		8.23	d, 6.0	2, 3, 4, 5	2, 3, 4, 5	2, 3, 1-Thr	2, 3, 4, 5 2-Thr, 3-Thr
Oxo-Pro	1	172.7	-					

	2	54.2	6.55	dd, 10.0, 2.0	3, 5	3, 5	3, 1-Val	3, 5 2a-Sar, 2b-sar NMe
	3	41.8	2.32	d, 18.5	2, 5	2, 5	1	2, 5
			2.13	d, 13.0	2, 5	2, 5	1	2, 5
	4	208.0	-	-			-	
	5	53.7	3.83	d, 18.5	2, 3	2, 3	1, 2	2, 3
			3.90	dd, 18.5 12.0	2, 3	2, 3	1, 2	2, 3
Sar	1	166.4						
	2	51.28	2a, 4.54	d, 19.5	2b	2b, NMe	1, NMe, 1-Pro	2b, NMe, 2-
			2b, 3.95	d, 19.0	2a	2a, NMe	1, NMe, 1-Pro	oxopro 4-MeVal , 5- MeVal, NMe
	N-Me	34.7	2.88	S		2a, 2b	2, 1-Pro	2b, 2MeVal
MeVal	1	167.4	-	-				
	2	71.1	2.67	d, 8.5	3, 4, 5	3, 4, 5	1, 3, 4, 5, NMe	4, 5

3	26.8	2.60	d, 8.0	2, 4, 5	2, 4, 5	1, 3, 4, 5, NMe	4, 5
4	21.5	0.93	d, 6.0	2, 3	2, 3, 5	2, 3, 5	3
5	19.1	0.73	d, 6.0	2, 3	2, 3, 4	2, 3, 4	3
N-Me	39.0	2.91	S	-	2, 3	2, 1- Sar	2, 5, 2a-Sar, 2b- Sar

Chromophore

Position	δC	δН	J (Hz)	COSY	TOCSY	НМВС	NOESY
1	101.8	-					
2	147.3	-					
3	179.0	-					
4	113.4	-					
4a	144.9						
5	-						
5a	140.3						
6	127.6	-					
7	130.2	7.34	d, 8.0	8, 11	8, 11	5a, 9, 11-Me	11
8	126.0	7.56	d, 7.5	7, 11	7, 11	9a, 5a, 13	11

9 9a	132.1 128.4	-					
10	-	-					
11	14.9	2.52	S	7, 8	7, 8	5a, 6, 7	7, 8
12	7.6	2.18	S	-	-	3, 4, 4a	-
13	166.0	-					
14	165.8	-					




Figure S53. ^{1H}-NMR (500 MHz, CDCl₃) Spectrum Of Compound R2




Figure S54. 13 C NMR (125 MHz, CDCl₃) Spectrum Of Compound R2




Figure S55. DEPT135&90 (125 MHz, CDCl₃) Spectrum of Compound R2




Figure S56. Expansion of DEPT135 &90 (125 MHz, CDCl₃) Spectrum of Compound R2




Figure S57. Expansion of DEPT135 &90 (125 MHz, CDCl₃) Spectrum of Compound R2




Figure S58. COSY (500 MHz) Spectrum of Compound R2




Figure S59. DQF-COSY (500 MHz) Spectrum of Compound R2




Figure S60. HMBC (500 MHz) Spectrum Compound of R2




Figure S61. HSQC (500 MHz) Spectrum of Compound R2




Figure S62. TOCSY (500 MHz) Spectrum of Compound R2




Figure S63. NOESY (500 MHz) Spectrum of Compound R2




Figure S64. ¹H-NMR (500 MHz, CDCl₃) Spectrum of Compound R3




Figure S65. DQF-COSY (500 MHz, CDCl₃) Spectrum of Compound R3




Figure S66. HMBC (500 MHz) Spectrum of Compound R3




Figure S67. HSQC (500 MHz) Spectrum of Compound R3




Figure S68. TOCSY (500 MHz, CDCl₃) Spectrum of Compound R3




Figure S69. NOESY (500 MHz) Spectrum of Compound R3




Figure S70. MALDI-TOF MS Spectrum of Transitmycin (R1) (Molecular ion peak) (positive mode)




Figure S71. Expansion of MALDI-TOF MS Spectrum of Transitmycin (R1) (Molecular ion peak) (positive mode)




Figure S72. Expansion of MALDI-TOF MS Spectrum of Transitmycin (R1) (Molecular ion peak) (Negative mode)




Figure S73. MALDI-TOF MS Spectrum of R2 (Molecular ion peak) (positive mode)




Figure S74. Expansion of MALDI-TOF MS Spectrum of R2 (Molecular ion peak) (positive mode)




Figure S75. Expansion of MALDI-TOF MS Spectrum of R2 (Molecular ion peak) (Negative mode)




Figure S76. MALDI-TOF MS Spectrum of R3 (Molecular ion peak) (positive mode)




Figure S77. MALDI-TOF MS Spectrum of R3 (Molecular ion peak) (Negative mode)




Figure S78. MALDI-TOF MS Spectrum of Transitmycin (R1) (Positive mode)





Figure S79. MALDI-TOF MS Spectrum of Transitmycin (R1) (Negative mode)

Table S6. MALDI-TOF MS Spectral Fragmentation of Transitmycin (R1) (Positive mode)

211- β-Ring-Val-Oxo-Pro
233- α -Ring-Val-Pro
294-β-Ring-Oxo-Pro-Sar-NMeVal
295-Chromophore
297- β-Ring-Thr-Val-Oxo-Pro
357-α-Ring-Val-Pro-Sar-MeVal
371-β-Ring-Val-Oxo-Pro-Sar-MeVal
412-β-Ring-Val-Oxo-Pro-Sar-NMeVal
412-α-Ring-Val-Pro-Sar-NMeVal+859 (Y ion)
495-β-Ring-Thr-Val-Oxo-Pro-Sar-NMeVal
496-α-Ring-Thr-Val-Pro-Sar-NMeVal
464 α - Ring-Thr-Val-Oxo-Pro-Sar-NMeVal
746-Y-113 (MeVal)
747- α-Ring-Val-Pro-Sar-NMeVal+Y-MeVal+545.6
1291-495
1291=746-545
1291=651+621
1291=495+775
1291=859+432
1291=920+371
1291=796+495
495= β-Ring-Thr-Val-Oxo-Pro-Sar-NMeVal
495-371=124-23=101 MeVal (β-Ring-Thr-Val-Oxo-Pro-Sar)
371(β-Ring-Thr-Val-Oxo-Pro-Sar)
294 (β-Ring-Thr-Val-Oxo-Pro)






Figure S80. MALDI-TOF MS Spectrum of R2 (Positive mode)




Figure S81. MALDI-TOF MS Spectrum of R2 (Negative mode)




Figure S82. MALDI-TOF MS Spectrum of R3 (Positive mode)




Figure S83. MALDI-TOF MS Spectrum of R3 (Negative mode)




Figure S84. QTRAP MS/MS Transitmycin (R1) (Molecular ion peak) (Positive mode)




Figure S85 QTRAP MS/MS Transitmycin (R1) (Molecular ion peak [M+H]²⁺ (Positive mode)




Figure S86. QTRAP MS/MS of Transitmycin (R1) (Molecular ion peak) (Negative mode)




Figure S87. QTRAP MS/MS of R2 (Molecular ion peak) ((Positive mode)




Figure S88. QTRAP MS/MS of R2 [M+H]²⁺ ion peak (Positive mode)




Figure S 89. QTRAP MS/MS of R2 (Molecular ion peak (Positive mode)




Figure S90. QTRAP MS/MS of R3 Molecular ion peak (Positive mode)




Figure S91. QTRAP MS/MS of R3 (Molecular ion peak (Negative mode)




Figure S92. HR-ESI-MS Spectrum of Transitmycin (R1) (Positive mode)




Figure S93. HR-ESI-MS Spectrum of Transitmycin (R1) (Molecular ion Peak) (Positive mode)




Figure S94. HR-ESI-MS Spectrum of R2 (Positive mode)




Figure S95. HR-ESI-MS Spectrum of R2 (Molecular ion Peak) (Positive mode)




Figure S96. HR-ESI-MS Spectrum of R3 (Positive mode)




Figure S97. HR-ESI-MS Spectrum of R3 (Molecular ion Peak) (Positive mode)




Figure S98. LC-ESI-MS Spectrum of Transitmycin (R1) (Molecular ion peak) (Positive mode)




Figure S99. LC-ESI-MS Spectrum of Transitmycin (R1) (Positive mode)




Figure S100. LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)




Figure S101. LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)




Figure S102. LC-ESI-MS Spectrum of R2 (Positive mode)




Figure S103. LC-ESI-MS Spectrum of R2 (Molecular ion) (Positive mode)




Figure S104. LC-ESI-MS Spectrum of R3 (Positive mode)




Figure S105. LC-ESI-MS Spectrum of R3 (Positive mode)




Figure S106. EI-MS Spectrum of Transitmycin (R1) (Positive mode)




Figure S107. EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode)




Figure S108. EI-MS Spectrum of (R2) (Positive mode)




Figure S109 EI-MS Spectrum of (R3) (Positive mode)




Figure S110. CHN analysis data of Transitmycin (R1), R2, R3




Figure S111. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)




Figure S112. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)




Figure S113. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode mode)




Figure S114. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)





Figure S115. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)

a) TRANSITMYCIN (R1) OBTAINED BY **OTRAP LCMS/MS**



STRUCTURAL CHARACTERISATION OF PRODUCT IONS OF [MS2] THE [M+NA]+ IONS OF TRANSITMYCIN b) (R1) OBTAINED BY QTRAP LCMS/MS [MS2] OF 1291.6]

1291.6 = [M+H]+1291.6-113.1 = 1178.5 Loss of H-MeVal-OH1291.6-226.1 = 1065.5 Loss of 2XH-MeVal1291.6-297.4 = 994.2 Loss of Sar-2XH-MeVal-OH 1291.6-368.2 = 923.4 Loss of 2XSar-2XH-MeVal-OH1291.6-440.3 = 851.3 Loss of 2XSar-2XH-MeVal-OH 1291.6-495.2 = 796.4 Loss of H-Thr-Val-Oxo-Pro-Sar-MeVal-OH 1291.6- 608.4 = 683.2 Loss of H-Thr-Val-Oxo-Pro-Sar-McVal-OH + Loss of H-McVal-OH 1291.6- 634.1 = 657.5 Loss of H-Val-Pro- Sar-McVal-OH + Loss of H-Pro- Sar-MeVal-OH 1291.6-652.2 = 639.4 Loss of H-Val-Pro- Sar-MeVal-OH + Loss of H-Pro- Sar-MeVal-OH (18) 1291.6-772.7 = 518.3 Loss of H'-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH 1291.6-772.7 = 518.3 Loss of H'-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH 1291.6-804.0 = 487.0 Loss of H-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH (32) 1291.6-848.3 = 443.3 Loss of H-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH (32) 1291.6-886.3 = 405.3 Loss of H-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH 1291.6-957.2 = 334.4 Loss of H-Th-Val-Oxo-Pro-Sar-MeVal-OH + Loss of H-Th-Val-Pro-Sar-MeVal-OH

Figure S115 a-b Structural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MS. b Product ions [MS2] the [M+Na]+ ions Transitmycin (R1) obtained by QTRAP LCMS/MS [MS2] of 1291.6, 1291.6 [M+H]⁺, 1178.5 Loss of H-MeVal-OH, 1065.5 Loss of 2XH-MeVal, 994.2 Loss of Sar-2XH-MeVal-OH, 923.4 Loss of 2XSar-2XH-MeVal-OH, 851.3 Loss of 2XSar-2XH-MeVal-OH, 796.4 Loss of H-Thr-Val-Oxo-Pro-Sar-MeVal-OH, 683.2 Loss of H-Thr-Val-Oxo-Pro-Sar-MeVal-OH + Loss of H-MeVal-OH, 657.5 Loss of H-Val-Pro-Sar-MeVal-OH + Loss of H-MeVal-OH + Loss o MeVal-OH + Loss of H-Pro- Sar-MeVal-OH, 639.4 Loss of H-Val-Pro- Sar-MeVal-OH + Loss of H-Pro- Sar-MeVal-OH (18), 518.3 Loss of H`-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro-Sar-MeVal-OH, 518.3 Loss of H`-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro-Sar-MeVal-OH, 487.0 Loss of H-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH (32), 443.3 Loss of H-Val-OXO-Pro-Sar-MeVal-OH (32), 443.3 Loss of H-Val-OXO-Pro-Sar-Me MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH (32), 405.3 Loss of H-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH, 334.4 Loss of H-Th-Val-Oxo-Pro-Sar-MeVal-OH + Loss of H-Th-Val-Pro- Sar-MeVal-OH.

Table S7a. Structural characterisation of Transitmycin (R1) obtained by QTRAP LCMS/MS

Product ions of [MS2] the [M+H]⁺ ions of Transitmycin (R1) obtained by QTRAP LCMS/MS

[MS2] of 1269.7

 $1269.7 = [M+H]^+$

1269.7-313.2 = 956.5 Loss of H-Oxo-Pro-Sar-MeVal-OH

1269.7-412.5 = 857.2 Loss of H-Val-Oxo-Pro-Sar-MeVal-OH

1269.7-612.3 = 657.4 Loss of H-Val-Oxo-Pro-Sar-MeVal-OH + Loss of Sar-MeVal-OH

1269.7-711.3 = 558.4 Loss of H-Val-Oxo-Pro-Sar-MeVal-OH + Loss of Pro- Sar-MeVal-OH

1269.7-739.3 = 530.3 Loss of H-Val-Oxo-Pro-Sar-MeVal-OH + Loss of Pro- Sar-MeVal-OH (-28)

1269.7-810.4 = 459.3 Loss of H-Val-Oxo-Pro-Sar-MeVal-OH + Loss of Val-Pro- Sar-MeVal-OH

1269.7-870.4 = 399.3 Loss of H-Val-Pro- Sar-MeVal-OH

1269.7-969.7 = 300.2 Loss of H-Pro- Sar-MeVal-OH

1269.7-1007.5 = 262.2 Loss of H-Pro- Val-Sar-OH

1269.7-1066.3 = 203.4 Loss of H-Sar-MeVal-OH

1269.7-1100.4 = 169.3 Loss of H-Pro-Sar-OH

Table S7b. Structural characterisation of Transitmycin (R1) obtained by QTRAP LCMS/MS

Product ions of [MS2] the [M+Na]+ ions of Transitmycin (R1) obtained by QTRAP LCMS/MS

[MS2] of 1291.6]

 $1291.6 = [M+H]^{+}$

1291.6-113.1 = 1178.5 Loss of H-MeVal-OH

1291.6-226.1 = 1065.5 Loss of 2XH-MeVal

1291.6-297.4 = 994.2 Loss of Sar-2XH-MeVal-OH

1291.6-368.2 = 923.4 Loss of 2XSar-2XH-MeVal-OH

1291.6-440.3 = 851.3 Loss of 2XSar-2XH-MeVal-OH

1291.6-495.2 = 796.4 Loss of H-Thr-Val-Oxo-Pro-Sar-MeVal-OH

1291.6- 608.4 = 683.2 Loss of H-Thr-Val-Oxo-Pro-Sar-MeVal-OH + Loss of H-MeVal-OH

1291.6- 634.1 = 657.5 Loss of H-Val-Pro- Sar-MeVal-OH + Loss of H-Pro- Sar-MeVal-OH

1291.6-652.2 = 639.4 Loss of H-Val-Pro- Sar-MeVal-OH + Loss of H-Pro- Sar-MeVal-OH (18)

1291.6-772.7 = 518.3 Loss of H`-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH

1291.6-772.7 = 518.3 Loss of H'-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH

1291.6-804.0 = 487.0 Loss of H-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH (32)

1291.6-848.3 = 443.3 Loss of H-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH (32)

1291.6-886.3 = 405.3 Loss of H-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH

 $1291.6-957.2 = 334.4 \ Loss \ of \ H-Th-Val-Oxo-Pro-Sar-MeVal-OH + Loss \ of \ H-Th-Val-Pro-Sar-MeVal-OH + Loss \ of \ H-Th-$

The Transitmycin A (3.0 mg) dissolved in 6N HCl (1 mL) and heated at 110 0 C for 24 h. The solvent was removed under reduced pressure, and the resulting material was subjected to further derivatization. The hydrolysate mixture (3.5 mg) or the amino acid standards (0.5 mg) were dissolved in 0.1 mL of water and treated with 0.2 mL of 1% 1-fluoro-2,4-dinitrophenyl-5-Lalaninamide (FDAA) in acetone and 0.04 mL of 1.0 M sodium bicarbonate. The vials were heated at 50 0 C for 90 min, and the contents after cooling at room temperature were neutralized with 1 N HCl. After degassing, an aliquot of the FDAA derivative was diluted in MeOH and purified by chromatography using a RP C-18 column (250 X 4.6 mm) and a linear gradient of acetonitrile and water containing 0.05% trifluoroacetic acid from 20:80 to 50:50 in 20 min and then isocratic. The flow rate was 1 mL/min, and the absorbance detection was at 340 nm. The chromatogram was compared with those of amino acid standards treated in the same conditions. The above same procedure for other two compounds B and C were done.




Figure S116. Hydrolysis of Amino Acid Residue of Transitmycin (R1), R2, R3

Figure S117a. HPLC analysis of standard L-FDAA-D/L-Valine




Figure S117 b. HPLC analysis of standard L-FDAA-D-Valine




Figure S117c. HPLC analysis of standard L-FDAA-L-Valine




Figure S118 (a). HPLC analysis of standard L-FDAA-D/L-Proline




Figure S118 (b) HPLC analysis of standard L-FDAA-D-Proline




Figure S118c. HPLC analysis of standard L-FDAA-L-Proline




Figure S119a. HPLC analysis of standard L-FDAA-D/L-Threonine




Figure S119b. HPLC analysis of standard L-FDAA-D-Threonine







Figure S119c.HPLC analysis of standard L-FDAA-D-Threonine




S189


Figure S120a.HPLC analysis of standard L-FDAA-D/L-N-Methyl Valine
















Figure S121C. HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of Transitmycin (R1)














Figure S122c. HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of R2












Figure S123c. HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of R3




Figure S124. HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of (R2)




Figure S125. HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of R3




Table 8a. Analysis of L-FDAA derivates of acid hydrolysate of R2 by HPLC

Amino acids	HPLC retention times Marfey's derivatives of standard amino acids		HPLC retention time Marfey derivatives of	Assignment
	D	L	acid hydrolysate of Transitmycin R2	
Threonine	15.682	13.987	14.000	L
Proline	17.035	16.519	16.529 & 16.960	D&L
Valine	21.244	19.248	19.300	L
N-methyl valine	22.089	20.814	21.255	L

Table 8b. Analysis of L-FDAA derivatives of acid hydrolysate of R3 by HPLC

	HPLC retention times		HPLC retention time	
Amino acids	Marfey's derivatives of standard amino acids		Marfeyderivatives of	Assignment
	D	L	acid hydrolysate of Transitmycin R3	
Threonine	15.682	13.987	13.988	L
Proline	17.035	16.519	16.512 & 17.000	D&L
Valine	21.244	19.248	19.235	L
N-methyl valine	22.089	20.814	21.242	L




Figure S126. ESI- MS Spectrum of Marfey's Derivatives of Transitmycin (R1) (Positive mode)




Figure S127. ESI- MS Spectrum of Marfey's Derivatives of Transitmycin (R1) (Positive mode)




Figure S128. LCMS analysis of Standard L-FDAA-D-Proline (Positive mode)




Figure S129. LCMS analysis of Standard L-FDAA-D-Proline (Negative mode)




Figure S130 LCMS analysis of Standard L-FDAA-L-Proline (Positive mode)




Figure S131. LCMS analysis of Standard L-FDAA-L-Proline (Negative mode)




Figure S132. LCMS analysis of Standard L-FDAA-D/L-Proline (Positive mode)




Figure S133. LCMS analysis of Standard L-FDAA-D/L-Proline (Negative mode)




Figure S134.. LCMS analysis of Standard L-FDAA-D-Valine (Positive mode)




Figure S135. LCMS analysis of Standard L-FDAA-D-Valine (Negative mode)




Figure S136. LCMS analysis of Standard L-FDAA-L-Valine (Positive mode)




Figure S137. LCMS analysis of Standard L-FDAA-L-Valine (Negative mode)




Figure S138. LCMS analysis of Standard L-FDAA-D/L-Valine (Positive mode)




Figure S139. LCMS analysis of Standard L-FDAA-D/L-Valine (Negative mode)




Figure S140. LCMS analysis of Standard L-FDAA-D/L-Valine (Positive mode)




Figure S141. LCMS analysis of Standard L-FDAA-D/L-Valine (Negative mode)




Figure 142. LCMS analysis of Standard L-FDAA-D-Threonine (Positive mode)




Figure S143. LCMS analysis of Standard L-FDAA-D-Threonine (Negative mode)




Figure S144. LCMS analysis of Standard L-FDAA-D/L Threonine (Positive mode)




Figure 145. LCMS analysis of Standard L-FDAA-D/L Threonine (Negative mode)




Figure S146. LCMS analysis of Standard L-FDAA-D/L N-Methyl valine (Positive mode)




Figure S147. LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Positive mode)




Figure S148. LCMS analysis of Standard L-FDAA-L N-Methyl valine (Positive mode)




Figure S149. LCMS analysis of Standard L-FDAA-L- N-Methyl valine (Positive mode)




Figure S150. LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Positive mode)




Figure S151. LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Positive mode)




Figure S152. LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Negative mode)




Figure S153. LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Positive mode)




Figure S154. LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Positive mode)




Figure S155. LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Positive mode)




Figure S156. LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Negative mode)




Figure S157. LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Negative mode)




Figure S158. LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Negative mode)




Figure S159. LCMS analysis of L-FDAA derivatives of Transitmycin (R1) (Positive mode)




Figure S160. LCMS analysis of L-FDAA derivatives of R1 (Negative mode)




Figure S161. LCMS analysis of L-FDAA derivatives of R3 (Positive mode)

Table S9a. Analysis of L-FDAA derivates of acid hydrolysate of Transitmycin R2 by HPLCMS

	LCMS retention times		HPLC retention time	M+H]+	[M-H]-	Assignment
Amino acids	Marfey's derivatives of standard amino acids		Marfey derivatives of	m/z	m/z	
	D	L	acid hydrolysate of Transitmycin R1	Positive mode	Negative mode	
Threonine	9.90	13.50	13.73	372.13	370.13	L
Proline	15.16	14.31	14.23 &15.36	366.13	363.07	D&L
Valine	19.65	17.65	18.02	370.13	368.07	L
N-methyl valine	20.33	19.25	19.96	384.20	382.20	L

Table S9b. Analysis of L-FDAA derivates of acid hydrolysate of R3 by HPLCMS

	LCMS retention times		HPLC retention time	[M+H]+	[M-H]-	Assignment
Amino acids Marfey's derivatives of standard amino acids D minutes L minutes Marfey derivatives of acid hydrolysate of R3 minutes		standard amino acids	•	m/z	m/z	
		Positive mode	Negative mode			
Threonine	9.90	13.50	12.45	372.13	370.13	L
Proline	15.16	14.31	14.25	366.13	363.07	D & L
Valine	19.65	17.65	17.49	370.13	368.07	L
N-methyl valine	20.33	19.25	19.93	384.20	382.20	L

Table S10. Physico-chemical properties of R2

Colour: Red colour amorphous powder

Yield: 100 mg, 10%

m.p: 250-252°C

TLC: Rf = 0.6 (Ethyl acetate/Methanol, 95:5)

 $[\alpha]_D^{25}$: -24° (c = 0.2, MeOH)

Solubility: Soluble in Chloroform, Dichloromethane, Ethyl acetate, Methanol, Ethanol, Acetonitrile, DMSO, water.Insoluble in Hexane.

UV: $(MeOH) \lambda_{max}$, $(log \epsilon) 205$, (1.25), 240 (0.63), 425 (0.39), 442 (0.42) nm

CD: [MeOH, [nm], (mdeg)]: λ_{max} , ($\Delta \epsilon$) 195 (+8.8), 210 (-22.0), 240 (+4.3) nm

IR: (KBr), v_{max} = 3436, 2961, 2924, 2853, 1744, 1650, 1565, 1415, 1204, 1140, 1045, 1019 cm⁻¹

HRESI-MS: m/z(pos.ions) 650.3413 [M+2H]⁺², 1277.8245 [M + Na]⁺ 1293.8735 [M + K]⁺

 $C_{62}H_{86}N_{12}O_{16}Na [M + Na]^{+} calc. 1277.61824$, found. 1277.8245

Sar CH₃

H₃C

ΗÑ

H₃C

Thr

Val

Pro

H₃C

Val H₃Ć

CH₃

MeVal

ò

CH₃

H₃C

ĊH₃

NH Thr

 NH_2

Chromophore

MeVal

MALDI-TOF-MS: m/z (pos.ions) 1279.94914 [M + Na+2H]⁺ m/z (neg.ions) 1255.38052[M-H]⁻ [M + Na+2H]⁺ calc. 1279.63424, found.

1279.94914

LCESI-MS: m/z (pos.ions) 1277.8245 [M + Na]⁺ C₆₂H₈₆N₁₂O₁₆Na [M + Na]⁺ calc. 1277.61824, found. 1277.8245

EI-MS: (70 ev) *m/z* (pos.ions: 739.9827, 616.9573, 547.2778, 434.2708, 391.5160, 200.1560, 146.7755,

11.2256

CHN: Anal. calcd for C₆₂H₈₆N₁₂O₁₆C, 59.32; H, 6.90; N, 13.39.

Found: C, 61.05; H, 7.25; N, 11.32.

Table S11. Physico-chemical properties of R3

Colour: Orange colour amorphous powder (50 mg)

Yield: 50 mg, 5%

m.p: 220-222°C

R_{f:} 0.3 (Ethyl acetate-Methanol 95:5)

Solubility: Soluble in Chloroform, Dichloromethane, Ethyl acetateMethanol, Ethanol, Acetonitrile,

DMSO, water. Insoluble in Hexane

 $[\alpha]_D^{25}$: -27 ° (c = 0.2, MeOH)

UV (MeOH) λ_{ma} x(log ϵ) 206 (1.90), 240 (0.69) 424 (0.191), 442.2 (0.19) nm

CD: [MeOH,[nm], (mdeg)] $\lambda_{\text{max}}(\Delta \epsilon)$ 195 (+24.0), 210 (-21.5), 241 (+1.7)

IR:(KBr), v_{max} 3415, 2957, 2924, 2853, 1745, 1642, 1583, 1464, 1384, 1193, 1093, 1078 cm⁻¹.

HRESI-MS: m/z (pos.ions) 663.4698 [M+2H]⁺², 1271.7159 [M + H]⁺

 $C_{62}H_{86}N_{12}O_{17} [M + H]^{+} calc. 1277.6312$, found. 1271.7159

MALDI-TOF-MS: m/z (pos.ions) 1292.24097 [M + Na]⁺ m/z(neg.ions) 1268.48582[M-H]⁻

 $C_{62}H_{86}N_{12}O_{17}Na [M + Na]^{+} calc. 1293.61316$ found. 1292.24097

LCESI-MS: m/z (pos.ions) 1277.6149 [M-OH+Na+H]⁺ C₆₂H₈₅N₁₂O₁₆ [M – OH+Na+H]⁺ calc. 1277.61416, found. 1277.6149

EI-MS: (70 ev) *m/z* (pos.ions): 98, 956.7713, 900, 9470, 859.8045, 771.227, 708.0386, 562.4686,

515.1946, 446.3967, 351.8868, 1\230.2476, 94.2476

CHN: Anal. calcd for C₆₂H₈₆N₁₂O₁₇:C, 58.57; H, 6.82; N, 13.22.

Found: C, 58.75; H, 7.13; N, 11.59.

Supplementary Table 12: Drug resistant profile of the clinical isolates of *Mycobacterium tuberculosis* used to determine the anti TB activity of Transitmycin. R: Resistant; S: Susceptible. The drug resistant profile was determined by LJ based Proportion sensitivity method.

Culture No.	Isoniazid	Rifampicin	Kanamycin	Ofloxacin
1-49	S	S	S	S
50	R	S	S	S
51	R	S	S	S
52	S	R	S	S
53	R	S	S	S
54	S	S	S	R
55	R	S	S	S
56	R	S	S	R
57	R	S	S	S
58	R	S	S	S
59	R	S	R	R
60	R	R	R	S
61	S	S	R	S
62	R	S	S	R
63	R	S	S	R
64	R	S	R	R
65	R	S	S	S

66	R	S	S	R
67	R	S	S	R
68	R	S	R	R
69	S	S	S	R
70	S	S	S	R
71	R	S	S	S
72	R	S	S	R
73	R	R	S	S
74	R	S	S	S
75	R	R	S	S
76	R	R	R	S
77	R	R	S	R
78	R	R	S	R
79	R	S	S	S
80	R	S	S	R
81	R	S	S	S
82	R	R	S	S
83	R	R	S	S
84	R	R	S	R
85	R	R	S	S
86	R	R	S	R

87	S	R	S	R
88	R	R	S	S
89	R	R	S	S
90	S	R	S	R
91	S	S	S	R
92	R	R	S	S
93	R	R	S	R
94	S	R	S	R
95	R	S	S	R
96	R	R	S	S
97	R	S	S	R

S - Table 13. Anti-HIV activity of Transitmycin on various HIV-1 subtypes

HIV-1 subtype		EC ₅₀ Value (μM)				
	0	0.01	0.1	1	10	
SUB A	4624.7 ± 348.34	2600.31 ± 212.27	1413±84.36	116.00 ± 13.61	133.32 ± 13.33	0.263
SUB B	9123.78 ± 495.29	8419.48 ± 549.73	7470.78 ± 3208.54	4222.52 ± 138.79	1693.95±35.38	2.347
SUB C	11652.5 ± 1339.97	10962.821± 729.96	11005.35±144.9	3435.69 ± 75.80	578.46 ± 65.77	2.167
SUB D	10170.22 ± 1572	10761.7 ± 576.85	7405.783±303.46	1339.49±287.06	306.53± 27.43	0.447
SUB E	3976.34 ± 68.35	3726.96±590.53	2120.49±155.83	970.25 ±38.08	258.84 ± 3.87	0.78
SUB A/C	5871.52 ± 51.10	5562.45±396.06	4654.15 ±262.26	589.52 ± 133.80	154.45 ±30.20	0.685
NEV RES	3325.76 ± 259.01	3636.10 ±743.95	3278.46 ±329.16	627.37 ±69.58	341.00 ±7.88	0.771
AZT RES	3031.83 ± 821.87	3040.03±703.81	2213.102± 48.17	1066.38 ± 17.34	786.32 ±37.46	0.388

Acknowledgements for Characterisation of Transitmycin

The Chairman, NMR Research Centre, IISC, Bangalore

Dr.A.Mohan, Mr. Venkatesan, Department of Chemistry, IIT Madras

Dr.M.S.Moni, Dr.C. Baby, Mr. R. Bhaskar, SAIF IIT Madras for 2D NMR analysis

Prof. T. Pradeep, AnanyaBaksi, DST Unit of Nano science IIT Madras for QTRAP LC/MS/MS

Prof. T. Pradeep, Mr. Kamalesh, Mr. E. Sundaraj, DST Unit of Nano Science IIT Madras for MALDI-TOF

Mrs.Sunita Prakash, Molecular Biophysics Department, IISC Bangalore for ESI-MS/MS, MALDI TOF-MS/MS

Mrs.Santha, Mr.Thankarasu, Department of Chemistry IIT Madras for Q-TOF-ESI-MS

Mr. Sankar, SAIF, IIT Madras for IR, EI-MS

The Head, SAIF CDRI, Luknow for LC-ESI-MS

Mr.Muralidhar, SID IISC Bangalore LC-ESI-MS

Prof. Anju Chanda, Mr. T. Saravanan, Department of Biotech IIT Madras for Optical Rotation measurement

Mrs.S.Srividya, Department of Chemistry, IIT Madras.

Dr. P.M.Sivakumar, Department of Biotechnology, Indian Institute of Technology Madras, Chennai, Tamilnadu, 600036, India

Dr. Veluchamy Prabhawathi Department of Biotechnology, Indian Institute of Technology Madras, Chennai, Tamilnadu, 600036, India

Supplementary References:

- 1. Xiaoling Wang, Jioji Tabudravu Mostafa Ezzat Rateb, Krystal Joan Annand, Zhiwei Qin, Marcel Jaspars, Zixin Deng, Yi Yband Hai Deng, Identification and characterization of the actinomycin G gene cluster in Streptomyces iakyrus, *Mol. BioSyst.*, **9**, 1286—1289. (2013).
- 2. Rebecca H. Wills, Peter B. O'Connor Structural Characterization of Actinomycin D Using Multiple Ion Isolation and Electron Induced Dissociation J. Am. Soc. Mass Spectrom. **25**:186Y19, (2014).
- 3. IvanaCrnovci c, Siamak Semsary, Joachim Vater and Ullrich Keller, Biosynthetic rivalry of o-aminophenol-carboxylic acids initiates production of hemi-actinomycins in Streptomyces antibioticus, RSC Adv., **4**, 5065 (2014).
- 4. JoachimVater, Ivana Crnovčić, Siamak Semsary and Ullrich Keller MALDI-TOF mass spectrometry, an efficient technique for in situ detection and characterization of actinomycins, J. Mass Spectrom., 49, 210–222 (2014).
- **5.** Collisional Activation Decomposition of Actinomycins Using Tandem Mass Spectrometry J. Roboz, E. Nieves and J. F. Holland M. McCamish, C. Smith, BIOMEDICAL AND ENVIRONMENTAL MASS SPECTROMETRY, **VOL. 16**, 67-70 (1988).
- 6. A. B. Mauger, W. A. Thomas, NMR Studies of Actinomycins Varying at the Proline Sites, ORGANIC MAGNETIC RESONANCE, **VOL. 17,** NO. 3(1981).
- 7. Darren Thomas, Michael Morris, Jonathan M. Curtis and Robert K. Boyd, Fragmentation Mechanisms of Protonated Actinomycins and Their Use in Structural Determination of Unknown Analogues, JOURNAL OF MASS SPECTROMETRY, VOL. 30, 1111-1125 (1995).
- 8. Jens Bitzer, Martin Streibel, Hans-Jörg Langer, Stephanie Grond, First Y-Type Actinomycins from *Streptomyces*with Divergent Structure-Activity Relationships for Antibacterial and Cytotoxic Properties, *Org. Biomol. Chem.*, 7, 444–450. (2009).
- 9. Caixia Chen,Fuhang Song, QianWang,Wael M. Abdel-Mageed, HuiGuo, Chengzhang Fu &WeiyuanHou & Huanqin Dai & Xueting Liu & Na Yang & FengXie & Ke Yu & Ruxian Chen & Lixin Zhang, A marine-derived Streptomyces sp. MS449 produces high yield of actinomycin X2 and actinomycin D with potent anti-tuberculosis activity, Appl Microbiol Biotechnol 95:919–927, (2012).

- 10. Shigehiro Kamitori and FusaoTakusagawa' Multiple Binding Modes of Anticancer Drug Actinomycin D:X-ray, Molecular Modeling, and Spectroscopic Studies of d (GAAGCTTC)2-Actinomycin D Complexes and Its HostDNA, *J. Am. Chem. SOC.*, 116, 41544165, (1994).
- 11. JensBitzer, Victoria Gesheva, and Axel Zeeck, Actinomycins with Altered Threonine Units in the â-Peptidolactone, *J. Nat. Prod.*, **69**, 1153-1157, (2006).
- 12. Xiufang Zhang, Xuewei Ye, Weiyun Chai, Xiao-Yuan Lian, and Zhizhen Zhang, New Metabolites and Bioactive Actinomycins from Marine-Derived Streptomyces sp. ZZ338, Mar. Drugs, **14**, 181, (2016).
- 13. Helmut Lackner, Isabel Bahner, Nobuharu Shigematsu Lewis K. Pannell, and Anthony B. Mauger, Structures of Five Components of the Actinomycin Z Complex from *Streptomyces fradiae*, Two of Which Contain 4-Chlorothreonine, *J. Nat. Prod*, 63, 352-356, (2000).
- 14. F. Conti, P. DeSantis Conformation of Acitinomycin D Nature, Vol. 227, 19, (1970).